



University of Groningen

Noradrenergic and dopaminergic therapy in Parkinson's disease

Verhagen-Kamerbeek, Wilma Dianne Johanna

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date:

1994

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Verhagen-Kamerbeek, W. D. J. (1994). Noradrenergic and dopaminergic therapy in Parkinson's disease: preclinical studies on L-threo-DOPS, decarboxylase inhibitors and transdermal lisuride. Groningen: s.n.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

References

- Abercrombie ED, Keller RW Jr, Zigmond MJ (1988) Characterization of hippocampal norepinephrine release as measured by microdialysis perfusion: Pharmacological and behavioral studies. *Neuroscience* 27: 897-904
- Accuas E, Carboni E, De Ree RHA, Da Prada M, Di Chiara G (1992) Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyl-transferase inhibitor Ro 40-7592. *J Neurochem* 59: 326-330
- Adell A, Garcia-Marquez C, Armario A, Gelpi E (1988) Chronic stress increases serotonin and noradrenaline in rat brain and sensitizes their responses to a further acute stress. *J Neurochem* 50: 1678-1681
- Adér J-P, Sebens JB, Korf J (1980) Central levels of noradrenaline, 3-methoxy-4-hydroxyphenylethylene glycol and cyclic AMP in the rat after activation of locus coeruleus neurons: influence of single and repeated neuroleptic treatment. *Psychopharmacology* 70: 239-245
- Ahlskog JE, Kelly PJ, van Heerden JA, Stoddard SL, Tyce GM, Windebank AJ, Bailey PA, Bell GN, Bloxrud MD, Carmichael SW (1990) Adrenal medullary transplantation into the brain for treatment of Parkinson's disease: Clinical outcome and neurochemical studies. *Mayo Clin Proc* 65: 305-328
- Allen RM (1983) Role of amantadine in the management of neuroleptic induced extrapyramidal syndromes: overview and pharmacology. *Clin Neuropharmacol* 6 (Suppl 1): S64-S73
- Amberg G, Lindefors N (1989) Intracerebral microdialysis: II. Mathematical studies of diffusion kinetics. *J Pharmacol Method* 22: 157-183
- Andén N-E, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U (1970) Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. *Eur J Pharmacol* 11: 303-314
- Andén N-E, Fuxe K (1971) A new dopamine- β -hydroxylase inhibitor: effects on the noradrenaline concentration and on the action of L-Dopa in the spinal cord. *Brit J Pharmacol* 43: 747-756
- Andén N-E, Strömbom U, Svensson TH (1973) Dopamine and noradrenaline receptor stimulation: reversal of reserpine-induced suppression of motor activity. *Psychopharmacologia* 29: 289-298
- Andén N-E, Grabowska M (1976) Pharmacological evidence for a stimulation of dopamine neurons by noradrenaline neurons in the brain. *Eur J Pharmacol* 39: 275-282
- Anlezark GM, Crow TJ, Greenway AP (1973) Impaired learning and decreased cortical norepinephrine after bilateral locus coeruleus lesions. *Science* 181: 682-684
- Antelman SM, Szechtman H, Chin P, Fisher AE (1975) Tail-pinch-induced eating, gnawing and licking behavior in rats: dependence on the nigrostriatal dopamine system. *Brain Res* 99: 319-337
- Antelman SM, Caggiola AR (1977) Norepinephrine-dopamine interactions and behaviour. *Science* 195: 646-653
- Antelman SM, Knopf S, Kocan D, Edwards DJ (1989) Persistent sensitization of clonidine-induced hypokinesia following one exposure to a stressor: possible relevance to panic disorder and its treatment. *Psychopharmacology* 98: 97-101
- Araki H, Cheng J-T, Ohmura I, Tanaka C (1978) Positive chronotropic effect of three-3,4-dihydroxyphenylserine as a precursor of noradrenaline in rat isolated atria. *J Pharm Pharmacol* 30: 456-458
- Araki H, Tanaka C, Fujiwara H, Nakamura M, Ohmura I (1981) Pressor effect of L-threo-3,4-dihydroxyphenylserine in rats. *J Pharm Pharmacol* 33: 772-777
- Argiolas A, Mereu G, Serra G, Melis MR, Fadda F, Gessa GL (1982) N-n-propyl-norapomorphine: An extremely potent stimulant of dopamine autoreceptors. *Brain Res* 231: 109-116
- Aston-Jones G, Bloom FE (1981) Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. *J Neurosci* 1: 887-900
- Babinski J, Jarkowski B, Plichet V (1921) Kinésie paradoxale. Mutisme parkinsonien. *Rev Neurol* 37: 1266-1270
- Bäckström IT, Ross SB, Marcusson JO (1989) [3 H]Desipramine binding to rat brain tissue: binding to both noradrenaline uptake sites and sites not related to noradrenaline neurons. *J Neurochem* 52: 1099-1106
- Bannister R (1987) Autonomic involvement in Parkinson's disease. In: Rose FC (ed) *Parkinson's Disease: Clinical and Experimental Advances*. John Libbey, London, 55-57
- Baptista TJ, Hernandez L, Burguera JL, Burguera M, Hoebel BG (1990) Chronic lithium administration enhances serotonin release in the lateral hypothalamus but not in the hippocampus in rats. A microdialysis study. *J Neural Transm* [Gen Sect] 82: 31-41
- Barbeau A (1969) Parkinson's disease as a systemic disorder. In: Gillingham FJ, Donaldson IML (eds) *Third Symposium on Parkinson's Disease*, E & S Livingston Ltd, Edinburgh, 66-73
- Barbeau A (1973) Treatment of Parkinson's disease with L-DOPA and Ro 4-4602. Review and present status. *Adv Neurology* 2: 173-198
- Barbeau A, Roy M, Bernier G, Campanella G, Paris S (1987) Ecogenetics of Parkinson's disease: prevalence and environmental aspects in rural areas. *Can J Neuro Sci* 14: 36-41
- Barchas JD, Freedman DX (1963) Brain amines: response to physiological stress. *Biochem Pharmacol* 12: 1232-1235
- Barcroft H, Peterson E, Schwab RS (1952) Action of adrenaline and noradrenaline on the tremor in Parkinson's disease. *Neurology* 2: 154-160
- Barthel W, Markwardt F (1974) Aggregation of blood platelets by biogenic amines and its inhibition by antiadrenergic and antiserotonergic agents. *Biochem Pharmacol* 23: 37-45
- Bartholini G, Burkard WP, Pletscher A, Bates HM (1967) Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. *Nature* 215: 852-853
- Bartholini G, Constantinidis J, Tissot R, Pletscher A (1971) Formation of monoamines from various amino acids in the brain after inhibition of extracerebral decarboxylase. *Biochem Pharmacol* 20: 1243-1247
- Bartholini G, Keller HH, Pletscher A (1973) Effect of neuroleptics on endogenous norepinephrine in rat brain. *Neuropharmacology* 12: 751-756
- Bartholini G, Constantinidis J, Puig M, Tissot R, Pletscher A (1975) The stereoisomers of 3,4-dihydroxyphenylserine as precursors of norepinephrine. *J Pharmacol Exp Ther* 193: 523-532
- Bende MM, Bapat TR, Balsara JJ, Chandorkar AG (1990) Effects of yohimbine on dopamine dependent behaviours in rats and mice. *Indian J Physiol Pharmacol* 34: 195-200
- Ben-Sachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. *J Neurochem* 56: 1441-1444
- Benthem L (1993) Sympatho-adrenal regulation of energy metabolism. Thesis, Groningen, The Netherlands.
- Benveniste H, Diemer NH (1987) Cellular reactions to implantation of a microdialysis tube in the rat hippocampus. *Acta Neuropathol* 74: 234-238
- Benveniste H, Drejer J, Schousboe A, Diemer NH (1987) Regional cerebral glucose phosphorylation and blood flow after insertion of a microdialysis fibre through the dorsal hippocampus in the rat. *J Neurochem* 49: 729-734
- Benveniste H (1989) Brain dialysis. *J Neurochem* 52: 1667-1679
- Berger B, Gaspar P, Verney C (1991) Dopaminergic innervation of the cerebral cortex: Unexpected differences between rodents and primates. *Trends Neurosci* 14: 21-27
- Bergstrom DA, Kellar KJ (1979) Adrenergic and serotonergic receptor binding in the rat brain after chronic desmethylimipramine treatment. *J Pharmacol Exp Ther* 209:

- 256-261
- Bermejo FP, Calandre LH, Molina JA, Martinez P, De Yebenes JG (1986) Long-lasting drug holiday in Parkinson's disease. *Adv Neurology* 45: 503-506
- Berzheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington: clinical, morphological and neurochemical correlations. *J Neurol Sci* 20: 415-455
- Bhardwaj A, Brannan T, Martinez-Tica J, Weinberger J (1990) Ischemia in the dorsal hippocampus is associated with acute extracellular release of dopamine and norepinephrine. *J Neural Transm [Gen Sect]* 80: 195-201
- Biaggioni I, Hollister AS, Robertson RM, Robertson D (1987) Dopamine- β -hydroxylase deficiency in man. *Circulation* 76 Suppl IV: IV-299
- Biaggioni I, Robertson D (1987) Endogenous restoration of noradrenaline by precursor therapy in dopamine- β -hydroxylase deficiency. *Lancet* ii: 1170-1172
- Bindoff LA, Birch-Machin M, Cartledge NEF, Parker WD Jr, Turnbull DM (1989) Mitochondrial dysfunction in Parkinson's disease. *Lancet* ii: 49
- Birkmayer W, Hornykiewicz O (1961) Der L-Dioxyphenylalanin(=L-DOPA)-Effekt bei Parkinson Akinese. *Klin Wochenschr* 73: 787-788
- Birkmayer W, Hornykiewicz O (1962) Der L-dioxyphenylalanin (=L-DOPA)-Effekt beim Parkinson-Syndrom des Menschen: Zur Pathogenese und Behandlung der Parkinson-Akinese. *Arch Psychiat Nerven* 203: 560-574
- Birkmayer W, Mentasti M (1967) Weitere experimentelle Untersuchungen über den Catecholaminstoffwechsel bei extrapyramidalen Erkrankungen (Parkinson- und Chorea-Syndrom). *Archiv Psych Nerven* 210: 29-35
- Birkmayer W, Birkmayer G, Lechner H, Riederer P (1983) DL-3,4-threo-DOPS in Parkinson's disease: Effects on orthostatic hypotension and dizziness. *J Neural Transm* 58: 305-313.
- Blaschko H, Holton P, Sloane Stanley GH (1948) The decarboxylation of β -3:4-dihydroxyphenylserine (noradrenaline carboxylic acid). *Brit J Pharmacol* 3: 315-319
- Blaschko H, Burn JH, Langemann H (1950) The formation of noradrenaline from dihydroxyphenylserine. *Brit J Pharmacol* 5: 431-437
- Blaschko H, Chruscil TJ (1960) The decarboxylation of amino acids related to tyrosine and their awakening action in reserpine-treated mice. *J Physiol* 151: 272-284
- Bliss EI, Zwanziger J (1966) Brain amines and emotional stress. *J Psychiat Res* 4: 189-198
- Bolinder J, Ungerstedt U, Arner P (1993) Long-term continuous glucose monitoring with microdialysis in ambulatory insulin-dependent diabetic patients. *Lancet* 342: 1080-1085
- Bonuccelli U, Del Dotto P, Piccini P, Paoli C, Ceravolo R, Muratorio A (1994) Clozapine improves Levodopa-resistant parkinsonian tremor [Abstract]. *New Trends Clin Neuropharm* VIII: 290
- Boomsma F, van der Hoorn FAJ, Schalekamp MADH (1986) Determination of L-amino acid decarboxylase in human plasma. *Clin Chim Acta* 159: 173-183
- Borri Voltattorni C, Minelli A, Borri O (1981) The interaction of 2,3,4-trihydroxybenzylhydrazine with dopa decarboxylase from pig kidney. *Life Sci* 28: 103-108
- Borri Voltattorni C, Minelli A, Dominici P (1983) Interaction of aromatic amino acids in D and L forms with DOPA decarboxylase from pig kidney. *Biochemistry* 22: 2249-2254
- Boutelle MG, Zetterström T, Pei Q, Svensson L, Fillenz M (1990) In vivo neurochemical effects of tail pinch. *J Neurosci Methods* 34: 151-157
- Boyce S, Rupaik MJ, Tye S, Steventon MJ, Iversen S (1990) Modulatory role for CCK-B antagonists in Parkinson's disease. *Clin Neuropharmacol* 13: 339-347
- Bowsher RR, Henry DP (1986) Aromatic L-amino acid decarboxylase: biochemistry and functional significance. In: Boulton AA, Baker GB, Yu PH (eds) *Neurochemical Methods: Neurotransmitter Enzymes*. Humana Press, Clifton New Jersey, 33-77
- Bracco F, Albanese A, Barine P, Calloni F, Camerlingo M, Franchesci M, Piolti R, Scarpa M, Sterzi R, Dubini A (1994) L-Dopa sparing properties of a new dopamine agonist: Cabergoline [Abstract]. *New Trends Clin Neuropharm VIII*: 290-291
- Brannan T, Knott P, Kaufmann H, Leung L, Yahr M (1989) Intracerebral dialysis monitoring of striatal dopamine release and metabolism in response to L-DOPA. *J Neural Transm* 75: 149-157
- Brannan T, Martinez-Tica J, Yahr MD (1992) Changes in bodytemperature markedly affect striatal dopamine release and metabolism: an in vivo study. *J Neural Transm [Gen Sect]* 89: 193-196
- Burkard WP, Gey KF, Pletscher A (1964) Inhibition of decarboxylase of aromatic amino acids by 2,3,4-trihydroxybenzylhydrazine and its seryl derivative. *Arch Biochem Biophys* 107: 187-196
- Burns RS, Allen GS, Tulipan NB (1990) Adrenal medullary transplantation in Parkinson's disease: A review. *Adv Neurology* 53: 571-576
- Burns RS, Calne DB (1983) Disposition of dopaminergic ergot compounds following oral administration. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) *Lisuride and Other Dopamine Agonists*. Raven Press, New York, 153-160
- Burns R, Roznoski M, Da Prada M, Ebert M, Collins J (1991) Effect of COMT inhibitor Ro 40-7592 on plasma and ventricular CSF levels of DOPA and its metabolites in the rhesus monkey 10th International Symposium on Parkinson's disease, Tokyo [Abstract] 74
- Butcher SP, Fairbrother IS, Kelly JS, Arbuthnot GW (1988) Amphetamine-induced dopamine release in the rat striatum: An in vivo microdialysis study. *J Neurochem* 50: 346-355
- Calne DB, Teychene PF, Claveria LE, Eastman R, Greenacre K, Petrie A (1974) Bromocriptine in parkinsonism. *Brit Med J* 4: 442-444
- Calne DB (1982) Dopamine receptor agonists in the treatment of basal ganglia disorders. *Semin Neurol* 2: 359-364
- Caraceni T, Scigliano G, Musico M (1991) The occurrence of motor fluctuations in parkinsonian patients treated long-term with levodopa: role of early treatment and disease progression. *Neurology* 41: 380-384
- Carboni E, DiChiara G (1989) Serotonin release estimated by transcortical dialysis in freely-moving rats. *Neuroscience* 32: 637-645
- Carlsson A, Lindquist M, Magnusson T (1957) 3,4-dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. *Nature* 180: 1200
- Carlsson A (1964) Functional significance of drug-induced changes in brain monoamine levels. In: Himwich HE, Himwich WA (eds) *Progress in Brain Research* 8, Elsevier, Amsterdam, 9-27
- Carmichael SW, Wilson RJ, Brimjoin WS, Melton LJ III, Okazaki H, Yaksh TL, Ahlskog JE, Stoddard SI, Tyce GM (1988) Decreased catecholamines in the adrenal medulla of patients with parkinsonism. *New Engl J Med* 318: 254
- Carruba MO, Mantegazza P (1983) Behavioral pharmacology of ergot derivatives. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) *Lisuride and Other Dopamine Agonists*. Raven Press, New York, 65-77
- Cash R, Ruberg M, Raisman R, Agid Y (1984) Adrenergic receptors in Parkinson's disease. *Brain Res* 113: 268-275
- Cash R, Dennis T, l'Heureux R, Raisman R, Javoy-Agid F, Scatton B (1987) Parkinson's disease and dementia: norepinephrine and dopamine in locus coeruleus. *Neurology* 37: 42-46
- Cervera P, Rascol O, Ploska A, Gaillard G, Raisman R, Duyckaerts C, Hauw JJ, Scherman D, Montastruc JL, Javoy-Agid F, Agid Y (1988) Noradrenaline, adrenaline and tyrosine hydroxylase in adrenal medulla from Parkinsonian patients. *J Neurol Neurosurg Psychiat* 51: 1104-1105
- Chalmers JP, Reid JL (1972) Participation of central noradrenergic neurons in arterial baroreceptor reflexes in the rabbit. *Circulat Res* 31: 789-804
- Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without

- Chase TN, Gordon EK, Ng LKY (1973) Norepinephrine metabolism in the central nervous system of man: Studies using 3-methoxy-4-hydroxyphenylethylene glycol levels in cerebrospinal fluid. *J Neurochem* 21: 581-587
- Chase TN (1980) Dopamine degradation products in the cerebrospinal fluid of patients with extrapyramidal disorders. In: *Onderzoek van de Liquor Cerebrospinalis*. Boerhaave cursus, Rijksuniversiteit Leiden, 185-198
- Clemens JA, Smalstig EB, Sawyer BD (1974) Antipsychotic drugs stimulate prolactin release. *Psychopharmacologia* 40: 123-127
- Cohen G, Pasik P, Cohen B, Leist A, Mytilineou C, Yahr MD (1985) Pargyline and deprenyl prevent neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in monkeys. *Eur J Pharmacol* 106: 209-210
- Cohen G (1986) Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. *Adv Neurol* 45: 119-125
- Cohen G, Spina MB (1989) Deprenyl suppresses the oxidant stress associated with increased dopamine turnover. *Ann Neurol* 26: 689-690
- Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. *Neuropharmacology* 26: 1431-1440
- Colzi A, d'Agostini F, Kettler R, Borroni E, Da Prada M (1990) Effect of selective and reversible MAO inhibitors on dopamine outflow in rat striatum: a microdialysis study. *J Neural Transm Suppl* 32: 79-84
- Constantinidis J, Geissbühler F (1971) Problèmes de barrière capillaire pour les monoamines et leurs précurseurs. In: de Ajuriaguerra J, Gauthier G (eds) *Monoamines et Nouveaux Gris Centraux*. Georg et Masson, Geneva, 99-118
- Constas C (1962) The effects of adrenaline, noradrenaline, and isoprenaline on parkinsonian tremor. *J Neurol Neurosurg Psychiat* 25: 116-121
- Cools AR (1984) Basal ganglia and Parkinson's disease: neurobiological and pharmacological aspects in animals and man. *Clin Neurol Neurosurg* 86: 178-195
- Cote T, Munemura M, Kebabian J (1979) Lisuride hydrogen maleate: An ergoline with β -adrenergic antagonist activity. *Eur J Pharmacol* 59: 303-306
- Cote TE, Eskay RL, Frey EA, Grewe CW, Munemura M, Taurita K, Brown EM, Kebabian JW (1983) Actions of lisuride on adrenoceptors and dopamine receptors. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) *Lisuride and Other Dopamine Agonists*, Raven Press, New York, 45-53
- Cotzias GC, van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. *New Engl J Med* 276: 374-379
- Cotzias GC, Papavasiliou PS, Fehling C, Kaufman B, Mena I (1970) Similarities between neurological effects of L-dopa and of apomorphine. *New Engl J Med* 282: 31-33
- Creese I (1987) Biochemical properties of CNS dopamine receptors. In: Meltzer HY (ed) *Psychopharmacology: The Third Generation of Progress*. Raven Press, New York, 257-264
- Creveling CR, Daly J, Tokuyama T, Witkop B (1968) The combined use of α -methyltyrosine and 3-thio-dihydroxyphenylserine - selective reduction of dopamine levels in the central nervous system. *Biochem Pharmacol* 17: 65-70
- Cumming P, Damsma G, Fibiger HC, Vincent SR (1991) Characterization of extracellular histamine in the striatum and bed nucleus of the stria terminalis of the rat: An in vivo microdialysis study. *J Neurochem* 56: 1797-1803
- D'Amato RJ, Zweig RM, Whitehouse PJ, Wenk GL, Singer HS, Mayeux R, Price DL, Snyder SH (1987) Aminergic systems in Alzheimer's disease and Parkinson's disease. *Ann Neurol* 22: 229-236
- Damsma G, Westerink BHC, Imperato A, Rollema H, De Vries JB, Horn AS (1987) Automated brain dialysis of acetylcholine in freely moving rats: detection of basal acetylcholine. *Life Sci* 41: 873-876
- Damsma G, Boisvert DP, Mudrick LA, Wenkster D, Fibiger HC (1990) Effect of transient forebrain ischemia and pargyline on extracellular concentrations of dopamine, serotonin, and their metabolites in the rat striatum as determined by in vivo microdialysis. *J Neurochem* 54: 801-808
- Damsma G, Fibiger HC (1991) The effects of anaesthesia and hypothermia on interstitial concentrations of acetylcholine and choline in rat striatum. *Life Sci* 48: 2469-2474
- Daniel PM, Moorhouse SR, Pratt OE (1976) Do changes in blood levels of other aromatic amino acids influence levodopa therapy? *Lancet* i: 95
- Da Prada M, Picotti GB (1979) Content and subcellular localization of catecholamines and 5-hydroxytryptamine in human and animal blood platelets: monoamine distribution between platelets and plasma. *Br J Pharmacol* 65: 653-662
- Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE (1984) The pharmacology of Parkinson's disease: basic aspects and recent advances. *Experientia* 40: 1165-1171
- Da Prada M, Kettler R, Zürcher G, Schaffner R, Haefely WE (1987) Inhibition of decarboxylase and levels of dopa and 3-O-methyldopa: A comparative study of benzerazid versus carbidopa in rodents and of Madopar standard versus Madopar HBS in volunteers. *Eur Neurol Suppl* 1: 9-20
- Da Prada M, Zürcher G, Kettler R, Colzi A (1991) New therapeutic strategies in Parkinson's disease: inhibition of MAO-B by Ro 19-6327 and of COMT by Ro 40-7592. In: Bernardi G, Carpenter M, DiChiara G, Stanzione P (eds) *The Basal Ganglia III*, Plenum Press, New York, 723-732
- De Boer J (1993) Continuous chemical monitoring using microdialysis: Experimental and clinical studies. Thesis, Groningen, The Netherlands.
- DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. *Trends Neurosci* 13: 281-285
- DeMet EM, Halaris AE (1979) Origin and distribution of 3-methoxy-4-hydroxyphenylglycol in body fluids. *Biochem Pharmacol* 28: 3034-3050
- Den Hartog Jager WA, Bethlem J (1960) The distribution of Lewy bodies in the central and autonomic nervous system in idiopathic paralysis agitans. *J Neurol Neurosurg Psychiat* 23: 283-290
- Den Hartog Jager WA (1970) Histochemistry of adrenal bodies in Parkinson's disease. *Arch Neurol* 23: 528-533
- Denny-Brown D, Yanagisawa N (1976) The role of the basal ganglia in the initiation of movement. In: Yahr MD (ed) *The Basal Ganglia*, Raven Press, New York, 115-149
- DiChiara G (1990) In-vivo brain dialysis of neurotransmitters. *Trends Pharmacol Sci* 11: 116-121
- Dickinson SL, Gadie B, Tulloch IF (1988) α_1 - and α_2 -adrenoreceptor antagonists differentially influence locomotor and stereotyped behaviour induced by d-amphetamine and apomorphine in the rat. *Psychopharmacology* 96: 521-527
- Diederich N, Keipes M (1994) Use of clozapine for psychiatric complications of Parkinson's disease: results in 14 patients [Abstract]. *New Trends Clin Neuropharm* VIII: 294
- Dijk S, Krugers HJ, Korff J (1991) The effect of theophylline and immobilisation stress on haloperidol-induced catalepsy and on the metabolism in the striatum and hippocampus, studied with lactography. *Neuropharmacology* 30: 469-473
- Dingemans J, Korn A, Moritz E, Wallnofer A, Kneer J, Schäublil M, Zürcher G, Kettler R, Da Prada M, Koulou M (1994) Studies on combined treatment with moclobemide and antiparkinsonian drugs [Abstract]. *New Trends Clin Neuropharm* VIII: 295
- Dolphin A, Jenner P, Marsden CD (1976a) Noradrenaline synthesis from L-DOPA in rodents and its relationship to motoractivity. *Pharmacol Biochem Behav* 5: 431-439
- Dolphin AC, Jenner P, Marsden CD (1976b) The relative importance of dopamine and noradrenaline receptor stimulation for the restoration of motoractivity in reserpine or α -methyl-p-tyrosine pretreated mice. *Pharmacol Biochem Behav* 4: 661-670
- Donaldson IM, Dolphin AC, Jenner P, Pycock C, Marsden CD (1978) Rotational behaviour produced in rats by unilateral electrolytic lesions of the ascending noradrenergic bundles. *Brain Res* 138: 487-509
- Donoso AO, Bishop W, Fawcett CP, Krulich L, McCann SM (1971) Effects of drugs that modify brain monoamine

- concentrations on plasma gonadotropin and prolactin levels in the rat. *Endocrinology* 89: 774-784
- Dooley DJ, Jones GH, Robbins TW (1987) Noradrenaline- and time dependent changes in neocortical α_2 - and β_1 -adrenoceptor binding in dorsal noradrenergic bundle-lesioned rats. *Brain Res* 420: 152-156
- Drijfhout WJ, Grol CJ, Westerink BHC (1993) Microdialysis of melatonin in the rat pineal gland: Methodology and pharmacological applications. *J Neurochem* 61: 936-942
- Durrieu G, Senard JM, Tran MA, Rascol A, Montastruc JL (1991) Effects of levodopa and bromocriptine on blood pressure and plasma catecholamines in parkinsonians. *Clin Neuropharmacol* 14: 84-90
- Durso R, Szabo G, Davoudi H, Feldman RG (1989) Magnitude of response to levodopa in Parkinson's disease as it relates to peripheral and central measurements of levodopa and associated metabolites. *Clin Neuropharmacol* 12: 384-392
- Duvoisin RC (1986) Genetics of Parkinson's disease. *Adv Neurol* 45: 307-312
- Edmonds ME, Watkins PJ (1990) Clinical presentations of diabetic autonomic failure. In: Bannister R (ed) *Autonomic Failure*, 2nd Edition, Oxford University Press, 632-653
- Edwards DJ, Rizk M (1981) Effects of amino acid precursors on catecholamine synthesis in the brain. *Prog Neuropsychopharmacol* 5: 569-572
- Ehringer H, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamine (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. *Wien Klin Wochenschr* 38: 1236-1239
- Elizan TS, Moros DA, Yahr MD (1991) Early combination of selegiline and low-dose levodopa as initial symptomatic therapy in Parkinson's disease. Experience in 26 patients receiving combined therapy for 26 months. *Arch Neurol* 48: 31-34
- Elsworth JD, Redmond DE Jr, Roth RH (1982) Plasma and cerebrospinal fluid 3-methoxy-4-hydroxyphenylglycol (MHPG) as indices of brain norepinephrine metabolism in primates. *Brain Res* 235: 115-124
- Everett GM, Borcharding W (1970) L-Dopa: Effect on concentrations of dopamine, norepinephrine and serotonin in brains of mice. *Science* 168: 849-850
- Everitt BJ, Robbins T, Selden NRW (1990) Functions of the locus coeruleus noradrenergic system: A neurobiological and behavioural synthesis. In: Heal D, Marsden CA (eds) *The Pharmacology of Noradrenaline in the Central Nervous System*, Oxford University Press, Oxford, UK, 349-379
- Fabbrini G, Juncos JL, Mouradian MM, Serrati C, Chase TN (1987) Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. *Ann Neurol* 21: 370-376
- Fabbrini G, Mouradian MM, Juncos JL, Schlegel J, Mohr E, Chase TN (1988) Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms Part I. *Ann Neurol* 24: 366-371
- Factor SA, Wiener WJ (1993) Early combination therapy with bromocriptine and levodopa in Parkinson's disease. *Mov Disord* 8: 257-262
- Fahn S (1983) Fluctuations of disability in Parkinson's disease: pathophysiology. In: Marsden CD, Fahn S (eds) *Movement Disorders*. London, Butterworth, 123-145
- Fahn S (1991) Conclusions. In: Rinne UK, Nagatsu T, Horowski R (eds) *International Workshop Berlin Parkinson's disease*. Medicom, The Netherlands, 368-371
- Farley JI, Hornykiewicz O (1976) Noradrenaline in subcortical brain regions of patients with Parkinson's disease and control subjects. In: Birkmayer W, Hornykiewicz O (eds) *Advances in Parkinsonism*. Editions Roche, Basel, 178-185
- Faulk KF, Pascoe N, Maddaluno J, Greene KA, Wiener SG (1990) Passage of MHPG from plasma to CSF in a non-human primate. *J Neurosci Res* 27: 533-540
- Feiler D, Treves TA, Laor N, Rabey M, Korczyn AD (1994) Fluvoxamine in the treatment of depression in patients with Parkinson's disease [Abstract]. *New Trends Clin Neuropharm VIII*: 298-299
- Fellows LK, Boutelle MG, Fillenz M (1991) In vivo monitoring of brain glucose with microdialysis. In: Rolfe H, Westerink BHC, Drijfhout WJ (eds) *Monitoring Molecules in Neuroscience*. University Centre for Pharmacy, Groningen, The Netherlands, 20-22
- Ferre S, Guix G, Prat F, Jane F, Casas M (1990) Is catepsin properly measured? *Pharmacol Biochem Behav* 35: 753-757
- Finnegan KT, Skrott JJ, Irwin I, DeLanney LE, Langston JW (1990) Protection against DSP-4 induced neurotoxicity by deprenyl is not related to its inhibition of MAO-B. *Eur J Pharmacol* 184: 119-126
- Foote SL, Bloom FE, Aston-Jones G (1983) Nucleus locus coeruleus: New evidence of anatomical and physiological specificity. *Physiol Rev* 63: 844-914
- Foreman MM, Porter JC (1980) Effects of catechol estrogens and catecholamines on hypothalamic and corpus striatal tyrosine hydroxylase activity. *J Neurochem* 34: 1175-1183
- Forno LS (1982) Pathology of Parkinson's disease. In: Marsden CD, Fahn S (eds) *Movement Disorders*, Butterworth, London, 25-40
- Forno LS (1986) The Lewy body in Parkinson's disease. *Adv Neurol* 45: 35-43
- Forno LS, Langston JW, DeLanney LE, Irwin I, Ricaurte GA (1986) Locus coeruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. *Ann Neurol* 20: 449-455
- Foster NL, Newman RP, LeWitt PA, Gillespie MM, Larsen TA, Chase N (1984) Peripheral beta-adrenergic blockade treatment of parkinson tremor. *Ann Neurol* 16: 505-508
- Freed CR, Murphy RC (1978) Mass spectrometric measurement of catecholamine turnover in rat hypothalamus after long-term L-dopa infusion. *J Pharmacol Exp Ther* 205: 702-709
- Freed CR, Breeze RE, Rosenberg NL et al. (1992) Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. *New Engl J Med* 327: 1549-1555
- Fritschy J-M, Geffard M, Grzanna R (1990) The response of noradrenergic axons to systemically administered DSP-4 in the rat: An immunohistochemical study using antibodies to noradrenaline and dopamine- β -hydroxylase. *J Chem Neuroanat* 3: 309-321
- Fritschy J-M, Grzanna R (1989) Immunohistochemical analysis of the neurotoxic effects of DSP-4 identifies two populations of noradrenergic axon terminals. *Neuroscience* 30: 181-197
- Fritschy JM, Grzanna R (1991) Experimentally-induced neuron loss in the locus coeruleus of adult rats. *Exp Neurol* 111: 123-127
- Fujita K, Maruta K, Teradaira R, Beppu H, Shinpo K, Maeno Y, Ito T, Nagatsu T, Kato T (1977) Dopamine- β -hydroxylase activity in human cerebrospinal fluid and serum. *J Neurochem* 29: 1141-1142
- Fujiwara H, Inagaki C, Ikeda Y, Tanaka C (1976) Decarboxylation of stereoisomers of 3,4-dihydroxyphenylserine (DOPS) in vitro. *Folia Pharmacol Japon* 72: 891-898
- Fuxe K, Hökfelt T, Agnati LF (1978) Mapping out central catecholamine neurons: immunohistochemical studies on catecholamine synthesizing enzymes. In: Lipton MA, DiMascio A, Killam KF (eds) *Psychopharmacology: A Generation of Progress*. Raven Press, New York, 67-94
- Gai W-P, Geffen LB, Denoroy L, Blessing WW (1993) Loss of C1 and C3 epinephrine-synthesizing neurons in the medulla oblongata in Parkinson's disease. *Ann Neurol* 33: 357-367
- Ganong WF (1977) *Review of Medical Physiology*, 8th Edition, Lange Medical Publications, Los Altos, California, 171-175
- Gaspar P, Berger B, Alvarez C, Vigny A, Henry JP (1985) Catecholaminergic innervation of septal area in man: Immunocytochemical study using TH and DBH antibodies. *J Comp Neurol* 241: 12-33
- Gaspar P, Duyckaerts C, Alvarez C, Javoy-Agid F, Berger B (1991) Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson's disease. *Ann Neurol* 30: 365-374
- Gerfen CR (1992) The neostriatal mosaic: multiple levels of compartmental organization. *Trends Neurosci* 4: 133-139
- Geyer MA, Lee EH (1984) Effects of clonidine, piroxane and locus coeruleus lesion on the serotonergic and dopaminergic systems in raphe and caudate nucleus. *Biochem Pharmacol* 33: 3399-3404

- Giovanni P, Fetoni V, Genitrini S, Geminiani G, Caraceni T (1994) Cabergoline in advanced PD: Long-term experience [Abstract]. *New Trends Clin Neuropharm VIII*: 277
- Gibson CJ (1988) Increase in norepinephrine turnover after tyrosine or DL-threo-3,4-dihydroxyphenylserine (DL-threo-DOPS). *Life Sci* 42: 95-102
- Glavin GB (1985) Stress and brain noradrenaline: A review. *Neurosci & Biobehav Rev* 9: 233-243
- Glowinski J, Iversen LL (1966) Regional studies of catecholamines in the rat brain I. The disposition of [³H]-norepinephrine, [³H]-dopamine and [³H]-DOPA in various regions of the brain. *J Neurochem* 13: 655-669
- Goetz CG (1990) Dopaminergic agonists in the treatment of Parkinson's disease. *Neurology [Suppl 3]*: 50-54
- Goodwin BL, Johnson RD, Leask BGS, Ruthven CRJ, Sandler M (1972) Threo-3,4-dihydroxyphenylserine, a poor source of noradrenaline in the rat. *Experientia* 28: 1298-1299
- Gopinathan G, Terävalinen H, Dambrosia JM, Ward CD, Sanes JN, Stuart WK, Everts EV, Calne DB (1981) Lisuride in parkinsonism. *Neurology* 31: 371-376
- Gopinathan G, Horowski R, Suchy IH (1989) Lisuride pharmacology and treatment of Parkinson's disease. In: Calne DB (ed) *Drugs for the treatment of Parkinson's disease*. Springer-Verlag, Berlin, 471-513
- Gordon R, Spector S, Sjoerdsma A, Udenfriend S (1966) Increased synthesis of norepinephrine in the intact rat during exercise and exposure to cold. *J Pharmacol Exp Ther* 153: 440-447
- Gordon-Smith RH, Raxworthy MJ, Gulliver PA (1982) Substrate stereospecificity and selectivity of catechol-O-methyltransferase for DOPA, DOPA derivatives and α -substituted catecholamines. *Biochem Pharmacol* 31: 433-437
- Gower AJ, Berendsen HHG, Prinsen MM, Broekkamp CLE (1984) The yawning-penile erection syndrome as a model for putative dopamine autoreceptor activity. *Eur J Pharmacol* 103: 81-89
- Graybiel AM (1990) Neurotransmitters and neuromodulators in the basal ganglia. *Trends Neurosci* 13: 244-254
- Granerus A-K (1978) Factors influencing the occurrence of "on-off" symptoms during long-term treatment with L-dopa. *Acta Med Scand* 203: 75-85
- Grenhoff J, Svensson TH (1993) Prazosin modulates the firing pattern of dopamine neurons in rat ventral tegmental area. *Eur J Pharmacol* 233: 79-84
- Growdon JH, Ghika J, Tennis M, Cole DG, Schoenfeld D (1993) Noradrenergic mechanisms in progressive supranuclear palsy. In: Narabayashi H, Mizuno Y (eds) *Norepinephrine Deficiency and its Treatment with L-threo-DOPS in Parkinson's Disease and the Related Disorders*. The Parthenon Publishing Group, Carmforth, UK, 117-131
- Guerra-Romero L, Täuber MG, Fournier A, Tureen JH (1992) Lactate and glucose concentrations in brain interstitial fluid, cerebrospinal fluid, and serum during experimental pneumococcal meningitis. *J Infect Dis* 166: 546-550
- Haft I, Kranz PD, Albert FJ, Fani K (1972) Intravascular platelet aggregation in the heart induced by norepinephrine: microscopic studies. *Circulation* 46: 698-708
- Halbrügge T, Ungell A-L, Wölfel R, Graefe K-H (1988) Total body, systemic and pulmonary clearance and fractional extraction of unlabelled and differently ³H-labelled noradrenaline in the anaesthetized rabbit. *Naunyn-Schmiedeberg's Arch Pharmacol* 338: 361-367
- Halliday GM, Li YW, Blumbergs PC, Joh TH, Cotton RGH, Howe PRC, Blessing WW, Geffen LB (1990) Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. *Ann Neurol* 27: 373-385
- Halter JB, Beard JC, Porte D Jr (1984) Islet function and stress hyperglycemia: plasma glucose and epinephrine interaction. *Am J Physiol* 247: E47-E52
- Hardebo JE, Falck B, Owman C (1979) A comparative study on the uptake and subsequent decarboxylation of monoamine precursors in cerebral microvessels. *Acta Physiol Scand* 107: 161-167
- Hardebo JE, Owman C (1980) Barrier mechanisms for neurotransmitter monoamines and their precursors at the blood-brain interface. *Ann Neurol* 8: 1-11
- Hardie RJ, Lees AJ, Stern GM (1984) On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study. *Brain* 107: 487-506
- Harik SI, McGunigal Jr T (1984) The protective influence of the locus ceruleus on the blood-brain barrier. *Ann Neurol* 15: 568-574
- Herkenham M, Little M, Bankiewicz K, Yang S-C, Markey SP, Johannessen JN (1991) Selective retention of MPP⁺ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. *Neuroscience* 40: 133-158
- l'Heureux R, Dennis T, Curet G, Scatton B (1986) Measurement of endogenous noradrenaline release in the rat cerebral cortex in vivo by microdialysis: Effects of drugs affecting noradrenergic transmission. *J Neurochem* 49: 1794-1801
- Hillered L, Persson L, Pontén U, Ungerstedt U (1990) Neurochemical monitoring of the ischemic human brain using microdialysis. *Acta Neurochir* 102: 91-97
- Hirai M, Matsuoka Y, Nakajima T, Sano I (1975) Effects of 3,4-dihydroxyphenylserine on the concentration of brain noradrenaline and the level of plasma growth hormone of rats. *Med J Osaka Univ* 26: 51-59
- Hirsch E, Graybiel AM, Agid YA (1988) Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. *Nature* 334: 345-348
- Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. *Neurology* 17: 427-442
- Hoehn MM, Elton RL (1985) Low doses of bromocriptine added to levodopa in Parkinson's disease. *Neurology* 35: 199-206
- Hoeldtke RD, Cihni KM (1985) Effects of aging on catecholamine metabolism. *J Clin Endocrinol Metab* 60: 479-484
- Hoppe JO, Seppelin DK, Lands AM (1949) An investigation of the acute toxicity of the optical isomers of arterenol and epinephrine. *J Pharmacol Exp Ther* 95: 502-505
- Horellou P, Lundberg C, Le Bourdellès B, Victorin K, Brundin P, Kalén P, Björklund A, Mallet J (1991) Behavioural effects of genetically engineered cells releasing DOPA and dopamine after intracerebral grafting in a rat model of Parkinson's disease. *J Physiol (Paris)* 85: 158-170
- Hornykiewicz O (1974) The mechanisms of action of l-dopa in Parkinson's disease. *Life Sci* 15: 1249-1259
- Hornykiewicz O (1980) Biochemical abnormalities in some extrastriatal neuronal systems in Parkinson's disease. In: Rinne UK, Klingner M, Stamm G (eds) *Parkinson's Disease - Current Progress, Problems and Management*. Elsevier, Amsterdam, 109-119
- Hornykiewicz O (1982) Brain neurotransmitter changes in Parkinson's disease. In: Marsden CD, Fahn S (eds) *Movement Disorders*, Butterworth, London, 41-58
- Horowski R, Wachtel H (1976) Direct dopaminergic action of lisuride hydrogen maleate, an ergot derivative, in mice. *Eur J Pharmacol* 36: 373-383
- Horowski R, Wendt H, Gräf K-J (1978) Prolactin-lowering effect of low doses of lisuride in man. *Acta Endocrinol* 87: 234-240
- Horowski R (1986) Psychiatric side-effects of high-dose lisuride therapy in parkinsonism. *Lancet* ii: 510
- Hsiao JK, Ball BA, Morrison PF, Mefford IN, Bungay PM (1990) Effects of different semi-permeable membranes on in vitro and in vivo performance of microdialysis probes. *J Neurochem* 54: 1449-1452
- Hubble JP, Cao T, Hassanein RES, Neuberger JS, Koller WC (1993) Risk factors for Parkinson's disease. *Neurology* 43: 1693-1697
- Hümpel M, Nieuweboer B, Hasan SJ, Wendt H (1981) Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate; effects on plasma prolactin level. *Eur J Clin Pharmacol* 20: 47-51
- Hümpel M (1983) Pharmacokinetics of lisuride in animal species and humans. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) *Lisuride and Other Dopamine Agonists*. Raven Press, New York, 141-152
- Hurst JH, LeWitt PA, Burns RS, Foster NL, Lovenberg W

- (1985) CSF dopamine- β -hydroxylase activity in Parkinson's disease. *Neurology* 35: 565-568
- Hutton JT, Morris JL (1992) Long-acting carbidopa-levodopa in the management of moderate and advanced Parkinson's disease. *Neurology* 42 [Suppl 1]: 51-56
- Hyyppä MT, Långvik V-A, Rinne UK (1978) Plasma pituitary hormones in patients with Parkinson's disease treated with bromocriptine. *J Neural Transm* 42: 151-157
- Iacono R, Toyama S, Meltzer C (1994) The use of selective serotonin re-uptake inhibitors (SSRI) in treatment of Parkinson's disease [Abstract]. *New Trends Clin Neuropharm VIII*: 303
- Imperato A, DiChiara G (1984) Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: A new method for the study of in vivo release of endogenous dopamine and metabolites. *J Neurosci* 4: 966-977
- Imperato A, DiChiara G (1985) Dopamine release and metabolism in awake rats after systemic neuroleptics as studied by trans-striatal dialysis. *J Neurosci* 5: 297-306
- Imperato A, Tanda GL, Frau R, DiChiara G (1988) Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats. *J Pharmacol Exp Ther* 245: 257-264
- Inagaki C, Tanaka C (1978) Characteristics of enzymic decarboxylation of L-threo-3,4-dihydroxyphenylserine using hog renal L-aromatic amino acid decarboxylase. *Biochem Pharmacol* 27: 1081-1086
- Jacobson I, Hamberger A (1984) Veratridine-induced release in vivo and in vitro of amino acids in the rat olfactory bulb. *Brain Res* 299: 103-112
- Jacobson I, Sandberg M, Hamberger A (1985) Mass transfer in brain dialysis devices - a new method for the estimation of extracellular amino acids concentration. *J Neurosci Methods* 15: 263-268
- Jaeger CB, Teitelbaum G, Joh TH, Albert VR, Park DH, Reis DJ (1983) Some neurons of the rat central nervous system contain aromatic L-amino acid decarboxylase but not monoamine. *Science* 219: 1233-1235
- Jaim-Eicheverry G, Zieher LM (1980) DSP4: A novel compound with neurotoxic effects on noradrenergic neurons of adult and developing rats. *Brain Res* 188: 513-523
- Jankovic J (1990) Clinical aspects of Parkinson's disease. In: Marsden CD, Fahn S (eds) *The Assessment and Therapy of Parkinsonism*. Parthenon Publishing, New Jersey, 53-75
- Jarry H, Dikler E-M, Wuttke W (1985) Adrenal release of catecholamines and met-enkephaline before and after stress as measured by a novel in vivo dialysis method in the rat. *Neurosci Lett* 60: 273-278
- Javoy-Agid F, Taquet H, Ploska A, Cherif-Zahar C, Ruberg M, Agid Y (1981) Distribution of catecholamines in the ventral mesencephalon of human brain, with special reference to Parkinson's disease. *J Neurochem* 36: 2101-2105
- Javoy-Agid F, Pique L, Ruberg M, Ploska A, Taquet H, Bertagna X, Agid Y (1984) Biochemical analysis of hypothalamus in Parkinson's disease. *Neurology* 34: 672-675
- Jellinger KA (1991) Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. *Mol Chem Neuropharmacol* 14: 153-197
- Jenner P, Sheehy M, Marsden CD (1983) Noradrenaline and 5-hydroxytryptamine modulation of brain dopamine function: implications for the treatment of Parkinson's Disease. *Brit J Clin Pharmacol* 15: 277S-289S
- Jenner P, Dexter DT, Schapira AHV, Marsden CD (1990) Free radical involvement and altered iron metabolism as a cause of Parkinson's Disease. In: Marsden CD, Fahn S (eds) *The Assessment and Therapy of Parkinsonism*. The Parthenon Publishing Group Ltd., Carnforth, UK, 17-30
- Jimerson DC, Ballenger JC, Lake RM, Post RM, Goodwin FK, Kopin U (1981) Plasma and CSF MHPG in normals. *Psychopharmacol Bull* 7: 87-89
- Johansen PA, Wolf WA, Kuhn M (1991) Inhibition of tryptophan hydroxylase by benserazide and other catechols. *Biochem Pharmacol* 41: 625-628
- Johnson WG (1991) Genetic susceptibility to Parkinson's disease. *Geriatrics* 46 [Suppl 1]: 52-59
- Jonsson G, Hallman H, Ponzio F, Ross S (1981) DSP4 (N-(2-chloroethyl)-N-ethyl-2-bromobenzyl-amine) - a useful denervation tool for central and peripheral noradrenergic neurons. *Eur J Pharmacol* 72: 173-188
- Kaakkola S, Wurtman RJ (1992) Effects of COMT inhibitors on striatal dopamine metabolism: a microdialysis study. *Brain Res* 587: 241-249
- Kaakkola S, Teräväinen H, Ahlta S, Rita H, Gordin A (1994) Effect of entacapone, a COMT-inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. *Neurology* 44: 77-80
- Kachi T, Iwase S, Mano T, Saito M, Kunimoto M, Sobue I (1988) Effect of L-threo-3,4-dihydroxyphenylserine on muscle sympathetic nerve activities in Shy-Drager syndrome. *Neurology* 38: 1091-1094
- Kalén P, Kokaia M, Lindvall O, Björklund A (1988) Basic characteristics of noradrenaline release in the hippocampus of intact and 6-hydroxydopamine lesioned rats as studied by in vivo microdialysis. *Brain Res* 474: 374-379
- Kamberi IA, Mical RS, Porter JC (1970) Effect of anterior pituitary perfusion and intraventricular injection of catecholamines and indoleamines on LH release. *Endocrinology* 87: 1-12
- Karai N, Kato T, Katsuyama M, Nakamura M, Katsube J (1987) Effect of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) on brain and serum MHPG levels in mice: Evidence for NE formation in CNS. *Life Sci* 40: 2261-2268
- Karoum F, Korpi ER, Linnoila M, Chuang L-W, Wyatt RJ (1984) Reduced metabolism and turnover rates of rat brain dopamine, norepinephrine and serotonin by chronic desipramine and zimeldine treatments. *Eur J Pharmacol* 100: 137-144
- Kastner A, Hirsch EC, Herrero MT, Javoy-Agid F, Agid Y (1993) Immunocytochemical quantification of tyrosine hydroxylase at a cellular level in the mesencephalon of control subjects and patients with Parkinson's and Alzheimer's disease. *J Neurochem* 61: 1024-1034
- Kato T, Katsuyama M, Karai N, Hirose A, Nakamura M, Katsube J (1986) Reversal of the reserpine-induced ptosis by L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS), a (-)-norepinephrine precursor, and its potentiation by imipramine or nialamide. *Naunyn-Schmiedeberg's Arch Pharmacol* 332: 243-246
- Kato T, Karai N, Katsuyama M, Nakamura M, Katsube J (1987) Studies on the activity of L-threo-3,4-dihydroxyphenylserine (L-DOPS) as a catecholamine precursor in the brain: comparison with that of L-Dopa. *Biochem Pharmacol* 36: 3051-3057
- Katsube J, Kato T, Katsuyama M, Maeda Y, Nishikawa S, Nakamura M (1986) Diuretic effect of L-threo-3,4-dihydroxyphenylserine, a noradrenaline precursor, in rats and mice. *J Pharm Pharmacol* 38: 533-534
- Katsuyama M, Kato T, Karai N, Nakamura M, Katsube J (1986) Reversal by L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS), a l-norepinephrine precursor of reserpine- or tetrabenazine-induced hypothermia. *Arch Int Pharmacodyn* 283: 61-70
- Kehr W (1977) Effect of lisuride and other ergot derivatives on monoaminergic mechanisms in rat brain. *Eur J Pharmacol* 41: 261-273
- Keller HH, Bartholini G, Pletscher A (1973) Increase of 3-methoxy-4-hydroxyphenylethylene glycol in rat brain by neuroleptic drugs. *Eur J Pharmacol* 23: 183-186
- Keller HH, Burkard WP, Pieri L, Bonetti EP, Da Prada M (1978) Lisuride- and D-LSD-induced changes of monoamine turnover in the rat brain. *Adv Biochem Psychopharmacol* 19: 393-396
- Keller HH, Bonetti EP, Pieri L, Da Prada M (1983) Lisuride-induced mounting behavior and effects on the monoaminergic system in rat brain. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) *Lisuride and Other Dopamine Agonists*. Raven Press, New York, 79-87
- Keller HH, Schaffner R, Ehrsam H, Da Prada M (1987) Neurochemical and pharmacological effects of DOPS (L-

- three-DOPS) with and without blockade of peripheral L-aromatic amino acid decarboxylase (DDC) in rats and mice. [Abstract] 6th Int Catecholamine Symp, June 14-19, Jerusalem, P124
- Kim A, Adler L, Angrist B, Rotrosen J (1989) Efficacy of low-dose metoprolol in neuroleptic-induced akathisia. *J Clin Psychopharmacol* 9: 294-296
- Kish SJ, Shannak KS, Rajput AH, Gilbert JJ, Hornykiewicz O (1984) Cerebellar norepinephrine in patients with Parkinson's disease and control subjects. *Arch Neurol* 41: 612-614
- Klawans HL, Goetz C, Nausieda PA, Weiner WJ (1977) Levodopa-induced dopamine receptor hypersensitivity. *Ann Neurol* 2: 125-129
- Kobayashi RM, Palkovits, Jacobowitz DM, Kopin IJ (1975) Biochemical mapping of the noradrenergic projection from the locus coeruleus. *Neurology* 25: 223-233
- Kokaia M, Kalén M, Bengzon J, Lindvall O (1989) Noradrenaline and 5-hydroxytryptamine release in the hippocampus during seizures induced by hippocampal kindling stimulation: An in vivo microdialysis study. *Neuroscience* 32: 647-656
- Koller WC (1992) Initiating treatment of Parkinson's disease. *Neurology [Suppl 1]*: 33-38
- Kondo T (1991) L-three-DOPS - implications for pathophysiology of parkinsonian symptoms chronically treated with L-DOPA. In: Nagatsu T, Narabayashi H, Yoshida M (eds) *Parkinson's Disease. From Clinical Aspects to Molecular Basis*. Springer-Verlag, FRG, 201-215
- Kopin IJ, Gordon EK, Jimerson DC, Polinsky RJ (1983) Relation between plasma and cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylglycol. *Science* 219: 73-75
- Kopp N, Denoroy L, Tommasi M, Gay N, Chazot G, Renaud B (1982) Increase in noradrenaline-synthesizing enzyme activity in medulla oblongata in Parkinson's disease. *Acta Neuropathol* 56: 17-21
- Korf J, Aghajanian GK, Roth RH (1973) Increased turnover of norepinephrine in the rat cerebral cortex during stress: Role of the locus coeruleus. *Neuropharmacology* 12: 933-938
- Korf J, van Praag HM, Schut D, Nienhuis RJ, Lakke JPWF (1974) Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-DOPA therapy. *Eur Neurol* 12: 340-350
- Korf J, Venema K (1985) Amino acids in rat striatal dialysates: Methodological aspects and changes after electroconvulsive shock. *J Neurochem* 45: 1341-1348
- Korf J, Klein HC, Venema K, Postema F (1988) Increases in striatal and hippocampal impedance and extracellular levels of amino acids by cardiac arrest in freely moving rats. *J Neurochem* 50: 1087-1096
- Koshimura K, Miwa S, Lee K, Hayashi Y, Hasegawa H, Hamahata K, Fujiwara M, Kimura M, Itokawa Y (1990) Effects of choline administration on in vivo release and biosynthesis of acetylcholine in the rat striatum as studied by in vivo brain microdialysis. *J Neurochem* 54: 533-539
- Koshiyama H, Kato Y, Ishikawa Y, Murakami Y, Inoue T, Imura H (1987) Stimulation of prolactin secretion by L-threo-3,4-dihydroxyphenylserine (L-DOPS) via central norepinephrine in the rat. *Life Sci* 41: 983-988
- Kostowski W, Jerlicz M, Bidzinski A, Hauptmann M (1977) Behavioral effects of neuroleptics, apomorphine and amphetamine after bilateral lesions of the locus coeruleus in rats. *Pharmacol Biochem Behav* 7: 289-293
- Kostowski W, Jerlicz M, Bidzinski A, Hauptmann M (1978) Evidence for existence of two opposite noradrenergic brain systems controlling behavior. *Psychopharmacology* 59: 311-312
- Kuczenski R, Segal DS (1992) Regional norepinephrine response to amphetamine using dialysis: comparison with caudate dopamine. *Synapse* 11: 164-169
- Kuhr WG, Korf J (1988) Extracellular lactic acid as an indicator of brain metabolism: Continuous on-line measurement in conscious, freely moving rats with intrastriatal microdialysis. *J Cereb Blood Flow Metab* 8: 130-137
- Kuz'min AI, Bogdanov MB, Medvedev OS (1992) A microdialysis investigation of the release of norepinephrine in the hypothalamus induced by 2-deoxyglucose in awake rats. *Neurosci Behav Physiol* 22: 436-439
- Laitinen L (1969) Desipramine in treatment of Parkinson's disease. A placebo-controlled study. In: Gillingham FJ, Donaldson IML (eds) *Third Symposium on Parkinson's Disease*, E & S Livingstone Ltd, Edinburgh, 173-176
- Lakke JPWF, Korf J, van Praag HM, Schut T (1972) The predictive value of the probenecid test for the effect of levodopa therapy in Parkinson's disease. *Nature (Lond)*, *New Biol* 236: 208-209
- Lakke JPWF, van den Burg W, Wiegman J (1982) Abnormalities in postural reflexes and voluntarily induced automatic movements in parkinsonian patients. *Clin Neurol Neurosurg* 84: 227-235
- Lakke JPWF (1985) Axial apraxia in Parkinson's disease. *J Neurol Sci* 69: 37-46
- Lakke JPWF, van den Burg W (1985) Observations on voluntarily induced automatic behavior in parkinsonism. In: Gerstenbrand F, Poewe W, Stern G (eds) *Clinical Experiences with Budipine in Parkinson Therapy*. Springer-Verlag, Berlin, 44-51
- Lang AE, Blair RDG (1989) Anticholinergic drugs and amantadine in the treatment of Parkinson's disease. In: Calne DB (ed) *Drugs for the Treatment of Parkinson's Disease*, Springer-Verlag, Berlin, 307-323
- Langer SZ (1987) Presynaptic regulation of monoaminergic neurons. In: Meltzer HY (ed) *Psychopharmacology: The Third Generation of Progress*, Raven Press, New York, 151-157
- Langston JW, Forno JS (1980) The hypothalamus in Parkinson's disease. *Ann Neurol* 3: 129-133
- Langston JW, Ballard P, Tetrud W, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. *Science* 219: 979-980
- Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. *Brain Res* 292: 390-394
- Langston JW, Koller WC, Giron LT (1992) Etiology of Parkinson's disease. In: Olanow CW, Lieberman A (eds) *The Scientific Basis for the Treatment of Parkinson's Disease*, The Parthenon Publishing Group, Camforth, UK, 33-58
- Lategan AJ, Marien MR, Colpaert FC (1990) Effects of locus coeruleus lesions on the release of endogenous dopamine in rat nucleus accumbens and caudate nucleus as determined by intracerebral microdialysis. *Brain Res* 523: 134-138
- Lategan AJ, Marien MR, Colpaert FC (1992) Suppression of nigrostriatal and mesolimbic dopamine release in vivo following noradrenaline depletion by DSP-4: a microdialysis study. *Life Sci* 50: 995-999
- Lazzarini AM, Myers RH, Zimmerman TR Jr, Mark MH, Golbe LI, Sage JI, Johnson WG, Duvoisin RC (1994) A clinical genetic study of Parkinson's disease: Evidence for dominant transmission. *Neurology* 44: 499-506
- Lehman A (1989) Effects of microdialysis-perfusion with anisotonic media on extracellular amino acids in the rat hippocampus and skeletal muscle. *J Neurochem* 53: 525-535
- Lenders JWM, Kvetnansky R, Pacak K, Goldstein DS, Kopin IJ, Eisenhofer G (1993) Extraneuronal metabolism of endogenous and exogenous norepinephrine and epinephrine in rats. *J Pharmacol Exp Ther* 266: 288-293
- Leira J, Herranz AS, Herreras O, Abaira V, Martín del Río R (1986) In vivo determination of extracellular concentration of amino acids in the rat hippocampus. A method based on brain dialysis and computerized analysis. *Brain Res* 384: 145-155
- Lewis MS, Molliver MB, Morrison JM, Lidov HD (1979) Complementarity of dopaminergic and noradrenergic innervation in anterior cingulate cortex of the rat. *Brain Res* 164: 327-333
- LeWitt PA, Gopinathan G, Ward CD, Sanes JN, Dambrosia JM, Durso R, Calne DB (1982) Lisuride versus bromocriptine treatment in Parkinson's disease: a double-blind study. *Neurology* 32: 69-72
- LeWitt PA, Ward CD, Larsen TA, Raphaelson MI, Newman RP, Foster N, Dambrosia JM, Calne DB (1983) Comparison

- of pergolide and bromocriptine therapy in parkinsonism. *Neurology* 33: 1009-1014
- Lieberman A, Goodgold A, Jonas S, Leibowitz M (1975) Comparison of dopa decarboxylase inhibitor (carbidopa) combined with levodopa and levodopa alone in Parkinson's disease. *Neurology* 25: 911-916
- Lieberman AN, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zazorin N, Walker R, Kleinberg D (1981) Lisuride in Parkinson's disease: Efficacy of lisuride compared to levodopa. *Neurology* 31: 961-965
- Lieberman AN, Goldstein M, Gopinathan G, Neophytides A, Leibowitz M, Walker R, Hiesiger E (1983) Lisuride in Parkinson's disease and related disorders. In: Calne DB, Horowski R, McDonald RJ, Wuttke W (eds) *Lisuride and Other Dopamine Agonists*. Raven Press, New York, 419-429
- Lieberman AN, Goldstein M (1985) Bromocriptine in Parkinson's disease. *Pharmacol Rev* 37: 217-227
- Lindfors N, Brodin E, Ungerstedt U (1987) Microdialysis combined with a sensitive radioimmunoassay. A technique for studying in vivo release of neuropeptides. *J Pharmacol Methods* 17: 305-312
- Lindfors N, Amberg G, Ungerstedt U (1989) Intracerebral microdialysis: I. Experimental studies of diffusion kinetics. *J Pharmacol Methods* 22: 141-156
- Lindvall O, Björklund A (1974) The glyoxylic acid fluorescence histochemical method: A detailed account of the methodology for the visualization of central catecholamine neurons. *Histochemistry* 39: 97-127
- Lloyd KG, Hornykiewicz O (1970) Parkinson's disease: activity of L-DOPA decarboxylase in discrete brain regions. *Science* 170: 1212-1213
- Lloyd KG, Hornykiewicz O (1972) Occurrence and distribution of aromatic L-amino acid (L-DOPA) decarboxylase in the human brain. *J Neurochem* 19: 1549-1559
- Lloyd KG, Davidson L, Hornykiewicz O (1973) Metabolism of levodopa in the human brain. *Adv Neurol* 3: 173-188
- Lloyd KG, Davidson L, Hornykiewicz O (1975) The neurochemistry of Parkinson's disease: Effect of L-DOPA therapy. *J Pharm Exp Ther* 195: 453-464
- Lönnerth P, Jansson P-A, Smith U (1987) A microdialysis method allowing characterization of intercellular water space in humans. *Am J Physiol* 253: E3228-E3231
- Löschmann PA, Lange KW, Kunow M, Rettig K-J, Jähmig P, Honoré T, Turski L, Wachtel H, Jenner P, Marsden CD (1991) Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CP with L-Dopa models of Parkinson's disease. *J Neural Transm [P-D Sect]* 3: 203-213
- Lovenberg WH, Weissbach H, Udenfriend S (1962) Aromatic L-amino acid decarboxylase. *J Biol Chem* 237: 89-93
- Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. *J Biol Chem* 193: 265-275
- Maertens de Noordhout A, Pepin JL, Delwaide PJ (1994) Open study of tizanidine in the treatment of freezing gait [Abstract]. *New Trends Clin Neuropharm VIII*: 309-310
- Maj J, Grabowska M, Mogilnicka E (1971) The effect of L-DOPA on brain catecholamines and motility in rats. *Psychopharmacologia* 22: 162-171
- Maj J, Sowinska H, Kapturkiewicz Z, Sarnak J (1972) The effect of L-Dopa and (+)-amphetamine on the locomotor activity after pimozide and phenoxylbenzamide. *J Pharm Pharmacol* 24: 412-413
- Major O, Shdanova T, Duffek L, Nagy Z (1990) Continuous monitoring of blood-brain barrier opening to C_1^{51} -EDTA by microdialysis following probe injury. *Acta Neurochirurg Suppl* 51: 46-48
- Man in 't Veld AJ, Boomsma F, Moleman P, Schalekamp MADH (1987) Congenital dopamine- β -hydroxylase deficiency. A novel orthostatic syndrome. *Lancet* i: 183-187
- Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Schalekamp MADH (1987) Effect of un-natural noradrenaline precursor on sympathetic control and orthostatic hypotension in dopamine-beta-hydroxylase deficiency. *Lancet* ii: 1172-1175
- Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Julien C, Lenders J, Schalekamp MADH (1988) D,L-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension in dopamine-beta-hydroxylase deficiency. *J Hypertens* 6 [Suppl 4]: 547-549
- Mann JJ, Stanley M, Kaplan RD, Sweeney J, Neophytides A (1983) Central catecholamine metabolism in vivo and the cognitive and motor deficits in Parkinson's disease. *J Neurol Neurosurg Psychiatr* 46: 905-910
- Markianos ES, Rütger E (1977) Serum dopamine-beta-hydroxylase in parkinsonism. *J Neural Transm* 40: 21-25
- Markianos M, Hadjikonstantinou M, Bistolaki E (1982) Urinary noradrenaline and serotonin metabolite in drug-free Parkinson patients and the effect of L-Dopa treatment. *Acta Neurol Scand* 66: 267-275
- Marsden CD (1969) Extending the use of anticholinergic drugs in Parkinson's disease. In: Gillingham FJ, Donaldson IML (eds) *Third Symposium on Parkinson's Disease*, E & S Livingstone Ltd, Edinburgh, 194-199
- Marsden CD, Dolphin A, Duvoisin RC, Jenner P, Tarsy D (1974) Role of noradrenaline in levodopa reversal of reserpine akinesia. *Brain Res* 77: 521-525
- Marsden CD, Parkes JD, Rees JE (1974) Propranolol in Parkinson's disease. *Lancet* ii: 410
- Marsden CD, Parkes JD (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. *Lancet* i: 292-296
- Marsden CD (1991) Major issues in the management of long-term treatment in Parkinson's disease. In: Rinne UK, Nagatsu T, Horowski R (eds) *International Workshop Berlin Parkinson's disease*. Medicom, The Netherlands, 219-225
- Marignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G, Nappi G (1992) Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. *J Neural Transm [P-D Sect]* 4: 191-205
- Martin PJ (1967) *The Basal Ganglia and Posture*. Pitman Medical Publishing, London
- Mathias CJ, Bannister RB, Cortelli P, Heslop K, Polak JM, Raimbach S, Springall DR, Watson L (1990) Clinical, autonomic and therapeutic observations in two siblings with postural hypotension and sympathetic failure due to inability to synthesize noradrenaline from dopamine because of a deficiency of dopamine beta hydroxylase. *Q J Med* 278: 617-633
- Matos FF, Taiwo Y, Rollema H, Levine J, Basbaum AI (1991) Microdialysis of morphine and serotonin in awake rats: A novel approach to study the pharmacodynamics of morphine. In: Rollema H, Westerink BHC, Drijthout WJ (eds) *Monitoring Molecules in Neuroscience*, University Centre for Pharmacy, Groningen, 381-383
- Matsubara S, Sawa Y, Yokoji H, Takamori M (1990) Shy-Drager syndrome. Effect of fludrocortisone and L-threo-3,4-dihydroxyphenylserine on the blood pressure and regional cerebral blood flow. *J Neurol Neurosurg Psychiatr* 53: 994-997
- Matsuo H, Takashima H, Kishikawa M, Kinoshita I, Mori M, Tsujihata M, Nagataki S (1991) Pure akinesia: an atypical manifestation of progressive supranuclear palsy. *J Neurol Neurosurg Psychiatry* 54: 397-400
- Mavridis M, Degryse A-D, Latagan AJ, Marien MR, Colpaert FC (1991) Effects of locus coeruleus lesions on parkinsonian signs, striatal dopamine and substantia nigra cell loss after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in monkeys: a possible role for the locus coeruleus in the progression of Parkinson's disease. *Neuroscience* 41: 507-523
- McDonald J, Horowski R (1983) Lisuride in the treatment of parkinsonism. *Eur Neurol* 22: 240-255
- McGeer PL, McGeer EG (1976) Enzymes associated with the metabolism of catecholamines, acetylcholine and GABA in human controls and patients with Parkinson's disease and Huntington's chorea. *J Neurochem* 26: 65-76
- McGeer EG, McGeer PL (1989) Biochemical neuroanatomy of the basal ganglia. In: Calne DB (ed) *Drugs for the Treatment of Parkinson's Disease*. Handbook of Experimental Pharmacology 88, Springer-Verlag, Berlin, 113-148
- Melamed E, Hefli F, Biton V, Globus M (1984) Suppression of

- L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: Implications for mechanism of action of L-dopa in parkinsonism. *Neurology* 34: 1566-1570
- Merello M, Lees A, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute levodopa in patients with Parkinson's disease. *J Neurol Neurosurg Psychiatr* 57: 186-189
- Meyerson BA, Linderöth B, Karlsson H, Ungerstedt U (1990) Microdialysis in the human brain: Extracellular measurements in the thalamus of parkinsonian patients. *Life Sci* 46: 301-308
- Mindermann T, Landolt H, Langemann H, Gratzl O (1993) Zerebrale Mikrodialyse in neurologischer und neurochirurgischer Forschung und klinische Anwendung in Neurologie und Neurochirurgie. *Schweizerische Rundschau für Medizin Praxis* 82: 9-11
- Mizoguchi K, Tanaka M, Yokoo H, Yoshida M, Tsuda A (1992) L-threo-3,4-dihydroxyphenylserine, a noradrenergic precursor, inhibits dopamine release and metabolism in the rat striatum in vivo. *Experientia* 48: 1133-1134
- Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. *J Neurochem* 54: 1755-1760
- Mogi M, Harada M, Kiuchi K, Kojima K, Kondo T, Narabayashi H, Rausch D, Riederer P, Jellinger K, Nagatsu T (1988) Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. *J Neural Transm* 72: 77-82
- Molander L, Randrup A (1974) Investigation of the mechanism by which L-DOPA induces gnawing in mice. *Acta Pharmacol Toxicol* 34: 312-324
- Molinari SP, Di Rocco A, Kollmeier AP, Yahr MD (1994) Long-term effect of ropinirole, a selective D-2 agonist, in the treatment of Parkinson's disease with on/off fluctuations [Abstract]. *New Trends Clin Neuropharm* VIII: 315
- Monasturic J-L, Villeneuve A, Berlan M, Lafontan M, Caranobe C, Boneu B, Rascol A (1986) Study of platelet α_2 -adrenoceptors in Parkinson's disease. *Adv Neurol* 45: 253-258
- Moore RY, Bloom FE (1979) Central catecholamine neuron systems: anatomy and physiology of the norepinephrine and epinephrine systems. *Ann Rev Neurosci* 2: 113-168
- Moore RY, Card PJ (1984) Noradrenergic-containing neuron systems. In: Björklund A, Hökfelt T (eds) *Handbook of Chemical Neuroanatomy, Vol 2, Classical Transmitters in the CNS, Part 1*, Elsevier, 123-155
- Mori M, Hashimoto H, Fukui K, Mori T, Noto T, Nakajima T (1987) Effects of L-erythro-3,4-dihydroxyphenylserine on sleep-wakefulness patterns and concentrations of brain catecholamines and serotonin in rats. *Jpn J Psychiatr Neurol* 41: 301-310
- Morimoto S, Matsumura Y, Ohyama T, Shinyama H, Ichihara T, Takahashi Y, Hisaki K (1990) Diuretic effects of L-threo-3,4-dihydroxyphenylserine (L-threo-DOPS) in anesthetized rats. *Japan J Pharmacol* 52: 431-439
- Mouradian MM, Heuser JJE, Baronti F, Chase TN (1990) Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. *Ann Neurol* 27: 18-23
- Myllylä VV, Sotaniemi KA, Sjaastad O, Rinne U, McIntyre T, Cremer G (1993) An open multicenter study of the efficacy of MDL 72,974A, a monoamine oxidase type B (MAO-B) inhibitor, in Parkinson's disease. *Adv Neurol* 60: 676-680
- Nagatsu T, Kato T, Nagatsu I, Kondo Y, Inagaki S, Iizuka R, Narabayashi H (1979) Catecholamine-related enzymes in the brain of patients with Parkinsonism and Wilson's disease. *Adv Neurol* 24: 283-292
- Nagatsu T, Wakui Y, Kato T, Fujita K, Kondo T, Yokochi F, Narabayashi H (1982) Dopamine- β -hydroxylase activity in cerebrospinal fluid of parkinsonian patients. *Biomed Res* 3: 95-98
- Nagatsu T (1991) Application of high-performance liquid chromatography to the study of biogenic amine-related enzymes. *J Chromatography* 566: 287-307
- Nagatsu T (1993) Biochemical aspects of Parkinson's disease. *Adv Neurol* 60: 165-174
- Nakahara H, Matsui K, Hara Y (1986) Hemodynamic effects of (-)-(2S,3R)-2-amino-3-hydroxy-3-(3,4-dihydroxyphenyl)propionic acid (L-threo-DOPS) in anesthetized open-chest rats. *Oyo Yakuri* 32: 1129-1136
- Nakamura M, Kato T, Katsuyama M, Karai N, Kumasaka Y, Shono F (1987) Penetration of L-threo-DOPS, a precursor of norepinephrine, into the brain in various experimental animals. *Jpn Pharmacol Ther* 15, Suppl 2: 119-125
- Nakamura S, Goshima Y, Yue JL, Miyamae T, Mitsu Y (1992) Transmitter-like 3,4-dihydroxyphenylalanine is tonically released by nicotine in striata of conscious rats. *Eur J Pharmacol* 222: 75-80
- Nakata T, Berard W, Kogosov E, Alexander N (1993) Cardiovascular change and hypothalamic norepinephrine release in response to environmental stress. *Am J Physiol* 264: R784-789
- Naoi M, Nagatsu T (1987) Uptake of L-threo-dihydroxyphenylserine into human brain synaptosomes. *J Neural Transm* 70: 51-61
- Narabayashi H, Kondo T, Nagatsu T (1982) L-threo-3,4-dihydroxyphenylserine treatment for freezing and akinesia in parkinsonism. *Neurology* 32 [Suppl 2]: 180
- Narabayashi H (1984) Akinesia in parkinsonism - clinical and pharmacological analysis of parkinsonian symptoms. *Bull Acad Med Bel* 139: 309-320
- Narabayashi H, Kondo T, Yokochi F, Nagatsu T (1986) Clinical effects of L-threo-3,4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia. *Adv Neurol* 45: 593-602
- Narabayashi H, Nakanishi T, Yoshida M, Yanagizawa N, Mizuno Y, Kanazawa I, Kondo T (1987) Therapeutic effects of L-DOPS in Parkinson's disease. Double-blind, comparative study against placebo as control in patients with long-term levodopa therapy. *Clin Eval* 15: 423-457
- Nisenbaum LK, Zigmund MJ, Sved AF, Abercrombie ED (1991) Prior exposure to chronic stress results in enhanced synthesis and release of hippocampal norepinephrine in response to a novel stressor. *J Neurosci* 11: 1478-1484
- Nishino N, Fuji Y, Kondo M, Shuntoh H, Fujiwara H, Tanaka C (1987) Effects of L-threo-3,4-dihydroxyphenylserine on efflux of monoamines and acetylcholine in guinea pig brain. *J Pharmacol Exp Ther* 242: 621-628
- Nutt JG, Woodward WR, Hammerstadt JP, Carter JH, Anderson JL (1984) The "on-off" phenomenon in Parkinson's disease. *N Engl J Med* 310: 483-488
- Nutt JG (1987) On-off phenomenon: relation to levodopa pharmacokinetics and pharmacodynamics. *Ann Neurol* 22: 535-540
- Obeso JA, Luquin MR, Martinez-Lage JM (1986) Lisuride infusion pump. A device for the treatment of motorfluctuations in Parkinson's disease. *Lancet* i: 467-470
- Obeso JA, Luquin MR, Martinez-Lage JM (1986) Intravenous lisuride corrects oscillations of motor performance in Parkinson's disease. *Ann Neurol* 19: 31-35
- Ogawa N, Kuroda H, Yamamoto M, Nukina I, Ota Z (1984) Improvement in freezing phenomenon of Parkinson's disease after DL-threo-3,4-dihydroxyphenylserine. *Acta Med Okayama* 38: 301-304
- Ogawa N, Yamamoto M, Takayama H (1985) L-threo-3,4-dihydroxyphenylserine treatment for Parkinson's disease. *J Med Clin Exp Ther* 16: 525-534
- Ogren SO, Archer T, Johansson C (1983) Evidence for a selective brain noradrenergic involvement in the locomotor stimulant effects of amphetamine in the rat. *Neurosci Lett* 43: 327-331
- Ohmura I, Inagaki C, Araki H, Tanaka C (1978) Enzymatic decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat heart. *Jpn J Pharmacol* 28: 747-753
- Okuno S, Fujisawa H (1991) Conversion of tyrosine hydroxylase to stable and inactive form by the end products. *J Neurochem* 57: 53-60
- Olanow CW, Cohen G (1992) The pathogenesis of Parkinson's disease. In: Olanow CW, Lieberman A (eds) *The Scientific Basis for the Treatment of Parkinson's Disease*, The Parthenon Publishing Group, Carnforth, UK, 59-76

- Orskov L, Jakobson J, Dupont E, de Fine Olivarius B, Christensen NJ (1987) Autonomic function in parkinsonian patients relates to duration of disease. *Neurology* 37: 1173-1178
- Osborne PG, O'Connor WT, Kehr J, Ungerstedt U (1991) In vivo characterisation of extracellular dopamine, GABA and acetylcholine from the dorsolateral striatum of awake freely moving rats by chronic microdialysis. *J Neurosci Meth* 37: 93-102
- Ozaki N, Nakahara D, Kaneda N, Kiuchi K, Okada T, Kasahara Y, Nagatsu T (1987) Acute effects of 1-methyl-4-phenylpyridinium ion (MPP⁺) on dopamine and serotonin metabolism in rat striatum as assayed in vivo by a microdialysis technique. *J Neural Transm* 70: 241-250
- Ozaki N, Nakahara D, Miura H, Kasahara Y, Nagatsu T (1989) Effects of apomorphine on in vivo release of dopamine and its metabolites in the prefrontal cortex and the striatum, studied by a microdialysis method. *J Neurochem* 53: 1861-1864
- Pacak K, Armando I, Komoly S, Fukuhara K, Kvetnansky R, Palkovits M, Kopin IJ, Goldstein DS (1992) Noradrenergic activation in the paraventricular nucleus during acute and chronic immobilisation stress in rats: an in vivo microdialysis study. *Brain Res* 589: 91-96
- Palacios JM, Kuhar MJ (1980) Beta-adrenergic receptor localization by light microscopic autoradiography. *Science* 208: 1378-1380
- Parkes JD, Schachter M, Marsden CD, Smith B, Wilson A (1981) Lisuride in parkinsonism. *Ann Neurol* 9: 48-52
- Parkinson Study Group (1994) A controlled trial of lazabemide (Ro 19-6327) in levodopa-treated Parkinson's disease. *Arch Neurol* 51: 342-347
- Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. 2nd ed Sydney, Academic Press.
- Peroutka SJ, U'Prichard DC, Greenberg DA, Snyder SH (1977) Neuroleptic drug interactions with norepinephrine alpha receptor binding sites in rat brain. *Neuropharmacology* 16: 549-556
- Persson B, Svensson TH (1981) Control of behaviour and brain noradrenaline neurons by peripheral blood volume receptors. *J Neural Transm* 52: 73-82
- Persson L, Hillered L (1992) Chemical monitoring of neurosurgical intensive care patients using intracerebral microdialysis. *J Neurosurg* 76: 72-80
- Pieri L, Keller HH, Da Prada M (1978) Effects of lisuride and LSD on cerebral monoamine systems and hallucinosis. *Nature* 272: 278-280
- Pieri L, Keller HH, Laurent J-P, Burkard WP, Pieri M, Bonetti EP, Da Prada M (1986) Behavioral, neurochemical, and electrophysiological effects of lisuride and LSD in animals. In: Caine DB, Horowski R, McDonald RJ, Wuttke W (eds) *Lisuride and Other Dopamine Agonists*, Raven Press, New York, 89-96
- Piff C, Schingnitz G, Hornykiewicz O (1991) Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. *Neuroscience* 44: 591-605
- Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS (1976) Levodopa and decarboxylase inhibitors: A review of their clinical pharmacology and the use in the treatment of Parkinsonism. *Drugs* 11: 329-377
- Plaznik A, Kostowski W (1983) The interrelationship between brain noradrenergic and dopaminergic neuronal systems in regulating animal behaviour: Possible clinical implications. *Psychopharmacol Bull* 19: 5-11
- Porceddu ML, Imperato A, Melis MR, DiChiara G (1983) Role of ventral mesencephalic reticular formation and related noradrenergic and serotonergic bundles in turning behaviour as investigated by means of kainate, 6-hydroxydopamine and 5,7-dihydroxytryptamine lesions. *Brain Res* 262: 187-200
- Porter CC, Torchiana ML, Stone CA (1972) (S)-Norepinephrine in the tissues of mice and rats given racemic erythro-3,4-dihydroxyphenylserine (DOPS). *Life Sci* 11: 787-795
- Porter CC (1973) Inhibitors of aromatic amino acid decarboxylase - their biochemistry. *Adv Neurol* 2: 37-58
- Pradham SN, Bose S (1978) Interactions among neurotransmitters. In: Lipton MA, DiMascio A, Killam KF (eds) *Psychopharmacology: A Generation of Progress*. Raven Press, New York, 271-281
- Prout BJ, Wardle WM (1969) Sweating and peripheral blood flow in patients with pheochromocytoma. *Clin Sci* 36: 109-117
- Puig M, Bartholini G, Pletscher A (1974) Formation of noradrenaline in the rat brain from the four stereoisomers of 3,4-dihydroxyphenylserine. *Arch Pharmacol* 281: 443-446
- Pycocck C (1977) Noradrenergic involvement in dopamine-dependent stereotyped and cataleptic responses in the rat. *Naunyn-Schmiedeberg's Arch Pharmacol* 298: 15-22
- Quinn N, Marsden CD, Parkes JD (1982) Complicated response fluctuations in Parkinson's disease: response to intravenous infusion of levodopa. *Lancet* ii: 412-415
- Quinn NP (1984) Anti-Parkinsonian drugs today. *Drugs* 28: 236-262
- Quinn NP, Perlmutter JS, Marsden CD (1987) Acute administration of DL-threo-DOPS does not affect the freezing phenomenon in parkinsonian patients [Abstract]. *Neurology* 34 [Suppl 1]: 149
- Rabey JM, Streifler M, Treves T, Korczyn AD (1989) A long-term comparative study of lisuride and levodopa in Parkinson's disease. In: Calne DB, Comi G, Crippa D, Horowski R, Trabucchi M (eds) *Parkinsonism and Aging*. Raven Press, New York, 261-267
- Rahman MK, Nagatsu T, Kato T (1981) Aromatic L-amino acid decarboxylase activity in central and peripheral tissues and serum of rats with L-DOPA and L-5-hydroxytryptophan as substrates. *Biochem Pharmacol* 30: 645-649
- Rahman MK, Nagatsu T, Kato T (1981) Determination of aromatic L-amino acid decarboxylase in serum of various animals by high performance liquid chromatography with electrochemical detection. *Life Sci* 28: 485-492
- Raichle ME, Harman BK, Eichling JO, Sharpe LG (1975) Central noradrenergic regulation of cerebral blood flow and vascular permeability. *Proc Natl Acad Sci USA* 72: 3726-3730
- Rajput AH, Rozdilsky B (1976) Dysautonomia in parkinsonism: A clinicopathological study. *J Neurol Neurosurg Psychiatr* 39: 1092-1100
- Reches A (1985) Noradrenergic influences on dopaminergic function and the pharmacology of dihydroxyphenylserine (DOPS): implication for Parkinson's disease. *Clin Neuropharmacol* 8: 249-259
- Reches A, Jackson-Lewis V, Fahn S (1985) DL-threo-DOPS as a precursor of noradrenaline. *Naunyn-Schmiedeberg's Arch Pharmacol* 331: 202-208
- Reinhard JF Jr, Shearin MD (1990) Inhibition of tyrosine-3-monoxygenase by benserazide. *Biochem Pharmacol* 39: 1489-1491
- Reis DJ, Molinoff PB (1972) Brain dopamine- β -hydroxylase: Regional distribution and effects of lesions and 6-hydroxydopamine on activity. *J Neurochem* 19: 195-204
- Reisine T (1981) Adaptive changes in catecholamine receptors in the central nervous system. *Neuroscience* 6: 1471-1502
- Reisine TD, Chesselet MF, Lubetzki C, Chérany A, Glowinski J (1982) A role for striatal beta-adrenergic receptors in the regulation of dopamine release. *Brain Res* 241: 123-130
- Rice HE, Smith CB, Silk KR, Rosen J (1984) Platelet alpha-adrenergic receptors in schizophrenic patients before and after phenothiazine treatment. *Psychiatr Res* 12: 69-77
- Riederer P, Birkmayer W, Seemann D, Wuketich S (1977) Brain noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. *J Neural Transm* 41: 241-251
- Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D (1978) CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies. *J Neural Transm [Suppl]* 14: 121-131
- Riederer P, Konradi C, Schay V, Kienzl E, Birkmayer G, Danielczyk W, Sofic E, Youdim MBH (1986) Localization of MAO-A and MAO-B in human brain: A step in understanding the therapeutic action of L-deprenyl. *Adv Neurol* 45: 111-118
- Rinne JO, Røytt M, Paljärvi L, Rummukainen J, Rinne UK (1991) Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease. *Neurology* 41: 859-861

- Rinne UK, Sonninen V, Laaksonen H (1979) Responses of brain neurochemistry to levodopa treatment in Parkinson's disease. *Adv Neurol* 24: 259-274
- Rinne UK (1983) Problems associated with long-term levodopa treatment of Parkinson's disease. *Acta Neurol Scand Suppl* 95: 19-26
- Rinne UK (1987) Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: A 5-year follow-up. *Neurology* 37: 826-828
- Rivest R, Marsden CA (1992) Differential effects of amfonelic acid on the haloperidol- and clozapine-induced increase in extracellular Dopac in the nucleus accumbens and the striatum. *Synapse* 10: 71-78
- Robert F, Lambas-Senas L, Orteman C, Pujol JF, Renaud B (1993) Microdialysis monitoring of 3,4-dihydroxyphenylalanine accumulation after decarboxylase inhibition: a means to estimate in vivo changes in tyrosine hydroxylase activity in the rat locus coeruleus. *J Neurochem* 60: 721-729
- Roberts JW, Cora-Locatelli G, Bravi D, Verhagen Metman L, Mouradian MM, Chase TN (1993) Catechol-O-methyltransferase (COMT) inhibitor Ro 40-7592 prolongs duration of action of levodopa/carbidopa in parkinsonian patients [Abstract]. *Neurology* 43: A332
- Robertson D, Haile V, Perry SE, Robertson RM, Phillips JA, Biaggioni I (1991) Dopamine- β -hydroxylase deficiency. A genetic disorder of cardiovascular regulation. *Hypertension* 18: 1-8
- Robertson GS, Robertson HA (1989) Evidence that L-Dopa-induced rotational behavior is dependent on both striatal and nigral mechanisms. *J Neurosci* 9: 3326-3331
- Ronne-Engström E, Hillered L, Flinck R, Spännare B, Ungerstedt U, Carlsson H (1992) Intracerebral microdialysis of extracellular amino acids in the human epileptic focus. *J Cereb Blood Flow Metab* 12: 873-876
- Roos RAC, Vredevoogd CB, van der Velde EA (1990) Response fluctuations in Parkinson's disease. *Neurology* 40: 1344-1346
- Rose S, Jenner P, Marsden CD (1991) Peripheral pharmacokinetic handling and metabolism of L-Dopa in the rat: the effect of route of administration and carbidopa pretreatment. *J Pharm Pharmacol* 43: 325-330
- Ross SB (1976) Long-term effects of N-2-chloroethyl-N-ethyl-2-bromobenzylamine hydrochloride on noradrenergic neurones in the rat brain and heart. *Br J Pharmacol* 58: 521-527
- Rossetti ZL, Pani L, Portas C, Gessa G (1989) Brain dialysis provides evidence for D₂-dopamine receptors modulating noradrenaline release in the rat frontal cortex. *Eur J Pharmacol* 163: 393-396
- Routledge C, Marsden CA (1987) Comparison of the effects of selected drugs on the release of hypothalamic adrenaline and noradrenaline measured in vivo. *Brain Res* 426: 103-111
- Rowland M, Tozer TN (1989) *Clinical Pharmacokinetics*, 2ed, Lea & Fibiger, Malvern, Pennsylvania
- Sachs C, Berglund B, Kaijser L (1985) Autonomic cardiovascular responses in parkinsonism: effect of levodopa with dopa-decarboxylase inhibition. *Acta Neurol Scand* 71: 37-42
- Sanberg PR (1980) Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors. *Nature* 284: 472-473
- Sanberg PR, Bunsey MD, Giordano M, Norman AB (1988) The catalepsy test: its ups and downs. *Behav Neurosci* 102: 748-759
- Sandler M, Fellows LE, Calne DB, Findley LJ (1975) Oxprenolol and levodopa in parkinsonian patients. *Lancet* i: 168
- Sandyk R (1989) Locus coeruleus-pineal melatonin interactions and the pathogenesis of the "on-off" phenomenon associated with mood changes and sensory symptoms in Parkinson's disease. *Int J Neurosci* 49: 95-101
- Saper CB, Sorrentino DM, German DC, de Lacalle S (1991) Medullary catecholaminergic neurons in the normal human brain and in Parkinson's disease. *Ann Neurol* 29: 577-584
- Sarna GS, Hutson PH, O'Connell MT, Curzon G (1991) Effect of tryptophan on extracellular concentrations of tryptophan and 5-hydroxyindoleacetic acid in the striatum and cerebellum. *J Neurochem* 56: 1564-1568
- Sarre S, Herregodts P, Devrieze A, Deleu D, De Klippel N, Ebinger G (1991) L-DOPA in striatum and substantia nigra of hemi-parkinson rats: bioavailability and biotransformation studied by microdialysis. In: Rollema H, Westerink BHC, Drijfhout WJ (eds) *Monitoring Molecules in Neuroscience*, Univ Centre for Pharmacy, Groningen, 407-408
- Sarre S, Herregodts P, Deleu D, Devrieze A, De Klippel N, Ebinger G, Michotte Y (1992) Biotransformation of L-DOPA in striatum and substantia nigra of rats with a unilateral, nigrostriatal lesion: a microdialysis study. *Naunyn-Schmiedeberg's Arch Pharmacol* 346: 277-285
- Sassin JF, Frantz AG, Wertzman EG, Kapen S (1972) Human prolactin: 24-hour pattern with increased release during sleep. *Science* 177: 1205-1207
- Sato S, Oyabe A, Tanno M, Suzuki-Kusaba M (1989) Beneficial attenuating effect of L-threo-3,4-dihydroxyphenylserine on postural hypo-tension in anesthetized rats. *Arzneim Forsch* 39: 1123-1129
- Sawle GV, Burn DJ, Morrish PK, Lammertsma AA, Snow BJ, Luthra S, Osman S, Brooks DJ (1994) The effect of entacapone (OR-611) on brain [¹⁸F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease. *Neurology* 44: 1292-1298
- Scatton B, Javoy-Agid F, Rouquier L, Dubois L, Agid Y (1983) Reduction of cortical dopamine, noradrenaline, serotonin, and their metabolites in Parkinson's disease. *Brain Res* 275: 321-328
- Scatton B, Dennis T, l'Heureux R, Montfort JC, Duyckaerts C, Javoy-Agid F (1986) Degeneration of noradrenergic and serotonergic but not dopaminergic neurons in the lumbar spinal cord of parkinsonian patients. *Brain Res* 380: 181-185
- Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. *J Neurochem* 54: 823-827
- Schapira AHV (1994) Evidence for mitochondrial dysfunction in Parkinson's disease - A critical appraisal. *Mov Disorders* 9: 125-138
- Schasfoort EMC, de Bruin LA, Korf J (1988) Mild stress stimulates rat hippocampal glucose utilization transiently via NMDA receptors, as assessed by lactography. *Brain Res* 475: 58-63
- Scheurink AJW, Steffens AB, Bouritius H, Dreteler GH, Bruntink R, Remie R, Zaagsma J (1989) Sympatho-adrenal influence on glucose, FFA, and insulin levels in exercising rats. *Am J Physiol* 256: R161-R168
- Schmitterlöw CG (1951) The formation in vivo of noradrenaline from 3:4-dihydroxyphenylserine (noradrenaline carboxylic acid). *Brit J Pharmacol* 6: 127-134
- Schoenberg BC (1986) Descriptive epidemiology of Parkinson's disease: Disease distribution and hypothesis formulation. *Adv Neurol* 45: 277-283
- Schoenberg BS, Osuntokun BO, Adejuga AOG, Bademosi O, Notidge V, Anderson DW, Haerer AF (1988) Comparison of the prevalence of Parkinson's disease in black populations in the rural United States and in rural Nigeria: Door-to-door community studies. *Neurology* 38: 645-646
- Schwartz DE, Brandt R (1978) Pharmacokinetic and metabolic studies of the decarboxylase inhibitor benserazide in animals and man. *Arzneim-Forsch/Drug Res* 28 (1): Heft 2: 302-307
- Seeman P, Van Tol HHM (1993) Dopamine receptor pharmacology. *Curr Opin Neurol Neurosurg* 6: 602-608
- Semba J, Takahashi R (1985) The effects of L-threo-3,4-dihydroxyphenylserine on norepinephrine metabolism in rat brain. *Psychiat Res* 15: 319-326
- Senard JM, Valet P, Durrieu G, Berlan M, Tran MA, Montastruc JL, Rascol A, Montastruc P (1990) Adrenergic supersensitivity in parkinsonians with orthostatic hypotension. *Eur J Clin Invest* 20: 613-619
- Sharp T, Foster GA (1989) In vivo measurement using microdialysis of the release and metabolism of 5-hydroxytryptamine in raphe neurons grafted to the rat hippocampus. *J Neurochem* 53: 303-306
- Sharp T, Branwell SR, Clark D, Grahame-Smith DG (1989) In vivo measurement of extracellular 5-hydroxytryptamine in hippocampus of the anesthetized rat using microdialysis:

- Changes in relation to 5-hydroxytryptaminergic neuronal activity. *J Neurochem* 53: 234-240
- Shimoi S, Matsui M, Yamada H, Matsuda T, Ichikawa Y, Mizushima Y (1994) Treatment of progressive supranuclear palsy with amtryptiline and L-threo-3,4-dihydroxyphenylserine (L-DOPS) [Abstract]. *New Trends Clin Neuropharm* VIII: 207
- Shono H, Sugihara K, Ohbe Y, Mizuno Y, Komuro S, Ito M, Kimura K, Nakatsuka I, Yoshitake A (1987) Absorption, distribution and excretion of L-DOPS in animals. *Jap Pharmacol Ther* 15, Suppl 2: 53-70
- Shoulson I, Glaubiger GA, Chase TN (1975) On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. *Neurology* 25: 1144-1148
- Shoulson I, Chase TN (1976) Clonidine and the anti-parkinsonian response to L-DOPA or pirbedil. *Neuropharmacology* 15: 25-27
- Shukla VK, Garg SK, Kulkarni SK (1986) Yohimbine potentiates the anticalcic action of clonidine against perphenazine-induced catalepsy in rats. *Arch Int Pharmacodyn Ther* 282: 44-49
- Shults CW, The Parkinson Study Group (1993) Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. *Acta Neurol Scand* 87, Suppl 146: 36-42
- Siegel S (1956) Nonparametric statistics for the behavioral sciences. McGraw-Hill Kogakusha, Tokyo
- Siever JL (1987) Role of noradrenergic mechanisms in the etiology of the affective disorders. In: Meltzer HY (ed) *Psychopharmacology. The Third Generation of Progress*. Raven Press, New York, 493-504
- Simpson RK, Robertson CS, Goodman JC (1990) Spinal cord ischemia-induced elevation of amino acids: Extracellular measurement with microdialysis. *Neurochem Res* 15: 635-639
- Sims KL, Bloom FE (1973) Rat brain L-3,4-dihydroxyphenylalanine and L-5-hydroxytryptophan decarboxylase activities: differential effect of 6-hydroxydopamine. *Brain Res* 49: 165-175
- Smith CCT, urtis LD, Delamothe AP, Prichard BNC, Betteridge DJ (1985) The distribution of catecholamines between platelets and plasma in normal human subjects. *Clin Sci* 69: 1-6
- Snyder AM, Stricker EM, Zigmond MJ (1985) Stress induced neurological impairments in an animal model of parkinsonism. *Ann Neurol* 18: 544-551
- Soares da Silva P (1993) Preferential decarboxylation of L-threo-3,4-dihydroxyphenylserine in rat renal tissues. *Gen Pharmacol* 24: 75-81
- Sofic E, Riederer P, Gsell W, Gavranovic M, Schmidtke A, Jellinger K (1991*) Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. *J Neural Transm [P-D Sect]* 3: 133-142
- Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MBH (1991*) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. *J Neurochem* 56: 978-982
- Ståhle L, Segersvärd S, Ungerstedt U (1991) A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis. *J Pharmacol Method* 25: 41-52
- Steffens AB (1969) A method for frequent sampling of blood and continuous infusion of fluids in the rat without disturbing the animal. *Physiol Behav* 4: 833-836
- Steiger MJ, Stocchi F, Carta A, Ruggieri S, Agnoli A, Quinn NP, Marsden CD (1991) The clinical efficacy of oral levodopa methyl ester solution in reversing afternoon "off" periods in Parkinson's disease. *Clin Neuropharmacol* 14: 241-244
- Stern Y, Mayeux R, Cote L (1984) Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism. *Arch Neurol* 41: 1086-1089
- Sternberg DE, van Kammen DP, Lake CR, Ballenger JC, Marder SR, Bunney WE (1981) The effect of pimozide on CSF norepinephrine in schizophrenia. *Am J Psychiatry* 138: 1045-1051
- Sübe CMH, Kempster PA, Lees AJ, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. *Lancet* i: 403-406
- Stocchi F, Bramante L, Monge A, Viselli F, Baronti F, Stefano E, Ruggieri S (1993) Apomorphine and lisuride infusion. A comparative chronic study. *Adv Neurol* 60: 653-655
- Stone EA (1973) Accumulation and metabolism of norepinephrine in rat hypothalamus after exhaustive stress. *J Neurochem* 21: 589-601
- Stone EA, Egawa M, Colbjornsen (1989) Catecholamine-induced desensitization of brain beta adrenoceptors in vivo and reversal by corticosterone. *Life Sci* 44: 209-213
- Stone EA, Zhang Y, John SM, Bing G (1991) c-Fos response to administration of catecholamines into brain by microdialysis. *Neurosci Lett* 133: 33-35
- Stoof JC, Booij J, Drukarch B, Wolters EC (1992) The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat striatum in a non-competitive way. *Eur J Pharmacol* 213: 439-443
- Suzuki T, Higa S, Tsuge I, Sakoda S, Hayashi A, Yamamura Y, Takaba Y, Nakajima A (1980) Effect of infused L-threo-3,4-dihydroxyphenylserine on adrenergic activity in patients with familial amyloid polyneuropathy. *Eur J Clin Pharmacol* 17: 429-435
- Suzuki T, Higa S, Sakoda S, Hayashi A, Yamamura Y, Takaba Y, Nakajima A (1981) Orthostatic hypotension in familial amyloid polyneuropathy: Treatment with DL-threo-3,4-dihydroxyphenylserine. *Neurology* 31: 1323-1326
- Suzuki T, Sakoda S, Ueji M, Kishimoto S, Hayashi A, Kondo T, Narabayashi H (1984) Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: A pharmacokinetic study. *Neurology* 34: 1446-1450
- Suzuki T, Sakoda S, Ueji M, Kishimoto S (1985) Mass spectrometric measurements of norepinephrine synthesis in man from infusion of isotope-labelled L-threo-3,4-dihydroxyphenylserine. *Life Sci* 36: 435-442
- Suzuki T, Higa S, Sakoda S, Ueji M, Azuma T (1987) Phase I study of L-threo-3,4-dihydroxyphenylserine (L-DOPS). *Jpn Pharmacol Ther* 15 [Suppl 2]: 381-400
- Svensson TH, Waldeck B (1969) On the significance of central noradrenaline for motor activity: experiments with a new dopamine β -hydroxylase inhibitor. *Eur J Pharmacol* 7: 278-282
- Svensson TH (1970) The effect of inhibition of catecholamine synthesis on dexamphetamine induced central stimulation. *Eur J Pharmacol* 12: 161-166
- Svensson TH (1971) On the role of central noradrenaline in the regulation of motor activity and body temperature in the mouse. *Naunyn-Schmiedeberg's Arch Pharmacol* 271: 111-120
- Svensson TH, Bunney BS, Aghajanian GK (1975) Inhibition of both noradrenergic and serotonergic neurons in brain by alpha-adrenergic agonist clonidine. *Brain Res* 92: 291-306
- Svensson TH (1987) Peripheral, autonomic regulation of locus coeruleus noradrenergic neurons in the brain: putative implications for psychiatry and psychopharmacology. *Psychopharmacology* 92: 1-7
- Swanson LW, Hartman BK (1975) The central adrenergic system. An immunofluorescence study of the location of cell bodies and their efferent connections in the rat utilizing dopamine β -hydroxylase as a marker. *J Comp Neurol* 163: 467-503
- Swart PJ, Toulouse FAM, De Zeeuw RA (1992) The influence of azone on the transdermal penetration of the dopamine D₂ agonist N-0923 in freely moving rats. *Int J Pharm* 88: 165-170
- Szemeredi K, Komoly S, Kopin IJ, Bagdy G, Keiser HR, Goldstein DS (1991) Simultaneous measurement of plasma and brain extracellular fluid concentrations of catechols after yohimbine administration in rats. *Brain Res* 542: 8-14
- Takács A, Tarczy M, Simó M, Szombathelyi É, Bodrogi A, Kárpáti R (1994) Moclobemide/aurorix/treatment in Parkinson's disease with depression [Abstract]. *New Trends Clin Neuropharmacol* VIII: 260
- Takita M, Mikuni M, Takahashi K (1992) Habituation of lactate release responding to stressful stimuli in rat prefrontal cortex

- in vivo. *Am J Physiol* 263: R722-727
- Takubo H, Kondo T (1988) Effects of L-threo-DOPS on monoamine metabolites and cyclic AMP in human cerebrospinal fluid - the evaluation of the mechanism for freezing phenomenon and akinesia. *Jpn J Neuropsychopharmacol* 10: 159-168
- Tanaka C, Nishino N (1985) Basic pharmacology of 3,4-dihydroxyphenylserine (L-threo-DOPS). *Shinkei Seishin Yakuri* 7: 779-793
- Tanner CM, Langston JW (1990) Do environmental toxins cause Parkinson's disease? A critical review. *Neurology* 40 [Suppl 3]: 17-30
- Tanner CM (1991) Liver enzyme abnormalities in Parkinson's disease. *Geriatrics* 46, Suppl 1: 60-63
- Taqet H, Javoy-Agid F, Cesselin F, Hamon M, Legrand JC, Agid Y (1982) Microtopography of methionin-enkephalin, dopamine and noradrenaline in the ventral mesencephalon of human control and parkinsonian brains. *Brain Res* 235: 303-314
- Tarsy D, Parkes D, Marsden CD (1975) Clonidine in Parkinson's disease. *Arch Neurol* 32: 134-136
- Teelken AW, van den Berg GA, Muskiet FAJ, Staal-Schreinemachers AL, Wolthers BG, Lakke JPWF (1989) Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease. *J Neural Transm [P-D Sect]* 1: 177-188
- Tetrad JW, Langston JW (1989) The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. *Science* 245: 519
- Teychenne PF, Feuerstein G, Lake CR, Ziegler MG (1985) Central catecholamine systems: Interaction with neurotransmitters in normal subjects and in patients with selected neurologic diseases. In: Lake CR, Ziegler MG (eds) *The Catecholamines in Psychiatric and Neurologic Disorders*, Butterworth Publishers, Boston, 91-119
- Thierry AM, Mantz J, Glowinski J (1992) Influence of dopaminergic and noradrenergic afferents on their target cells in the rat medial prefrontal cortex. *Adv Neurol* 57: 545-554
- Tissari AH, Gessa GL (1983) Ergot-induced inhibition of dopamine synthesis in striatal synaptosomes: A D-2 DA receptor-mediated mechanism. In: Calne DB, Horowski R, McDonald RJ, Wutke W (eds) *Lisuride and Other Dopamine Agonists*, Raven Press, New York, 33-43
- Tohgi H, Abe T, Takahashi S, Takahashi J, Ueno M, Nozaki Y (1990) Effect of a synthetic norepinephrine precursor, L-threo-3,4-dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. *Neurosci Lett* 116: 194-197
- Tohgi H, Abe T, Takahashi S (1993) The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. *J Neural Transm [P-D Sect]* 5: 27-34
- Toru M, Takashima M (1985) Haloperidol in large doses reduces the cataleptic response and increases noradrenaline metabolism in the brain of the rat. *Neuropharmacology* 24: 231-236
- Tossman U, Ungerstedt U (1986) Microdialysis in the study of extracellular levels of amino acids in the rat brain. *Acta Physiol Scand* 128: 9-14
- Tossman U, Eriksson LS, Delin A, Hagenfeldt D, Ungerstedt U (1987) Brain amino acids measured by intracerebral dialysis in porta-caval shunted rats. *Neurochem Res* 12: 265-267
- Tulen JHM, Man in 't Veld AJ, Dzoljic MR, Mechelse K, Moleman P (1991) Sleeping with and without norepinephrine: effects of metoclopramide and D,L-threo-3,4-dihydroxyphenylserine on sleep in dopamine beta-hydroxylase deficiency. *Sleep* 14: 32-38
- Turkka JT, Juujärvi KK, Lapinlampi TO, Myllylä VV (1986) Serum noradrenaline response to standing up in patients with Parkinson's disease. *Eur Neurol* 25: 355-361
- Turkka JT (1987) Correlation of the severity of autonomic dysfunction to cardiovascular reflexes and the plasma noradrenaline levels in Parkinson's disease. *Eur Neurol* 26: 203-210
- Turkka JT, Juujärvi KK, Myllylä VV (1987) Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease. *Eur Neurol* 26: 29-34
- Ueno E (1989) Clinical and physiological study of apraxia of gait and frozen gait. *Clin Neurol* 29: 275-283
- Ungerstedt U (1971) Stereotaxic mapping of the monoamine pathways in the rat brain. *Acta Physiol Scand [Suppl 376]*: 1-48
- Ungerstedt U (1984) Measurement of neurotransmitter release by intracranial dialysis. In: Marsden CA (ed) *Measurement of Neurotransmitter Release in vivo*. John Wiley & Sons Ltd., Chichester, 81-105
- Ungerstedt U (1991) Microdialysis - Principles and applications for studies in animal and man. *J Intern Med* 230: 365-373
- Van der Kuil JHF, Korf J (1991) On-line monitoring of extracellular brain glucose using microdialysis and a NADPH-linked enzymatic assay. *J Neurochem* 57: 648-654
- Van Veldhuizen MJA, Feenstra MGP, Boer GJ, Westerink BHC (1990) Microdialysis studies on cortical noradrenaline release: basic characteristics, significance of extracellular calcium and massive post-mortem increase. *Neurosci Lett* 119: 233-236
- Vermeulen RJ, Drukarch B, Sahadat MCR, Goosen C, Wolters ECH, Stoof JC (1993) The selective dopamine D₁ receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys. *Eur J Pharmacol* 235: 143-147
- Vermeulen RJ (1994) Effects of dopamine D₁ and D₂ receptor agonists on motor behavior of MPTP-lesioned monkeys. Thesis, Amsterdam, The Netherlands
- Vogel AI (1979) *Vogel's Textbook of Macro and Semimicro Qualitative Inorganic Analysis*. 5th edition, Longman Group Ltd, London, 243-246
- Vulto AG, Sharp T, Ungerstedt U, Versteeg DHG (1988) Rapid postmortem increase in extracellular dopamine in the rat brain as assessed by brain microdialysis. *J Neurochem* 51: 746-749
- Wade LA, Katzman R (1975) 3-O-Methyldopa uptake and inhibition of L-Dopa at the blood-brain barrier. *Life Sci* 17: 131-136
- Wakabayashi K, Takahashi H, Ohama E, Takeda S, Ikuta F (1993) Lewy bodies in the visceral autonomic nervous system in Parkinson's disease. *Adv Neurol* 60: 609-612
- Weiner WJ, Koller WC, Perlik S, Nausieda PA, Klawans HL (1980) Drug holiday and the management of Parkinson's disease. *Neurology* 30: 1257-1261
- Weinrich M, Koch K, Garcia F, Angel RW (1988) Axial versus distal motor impairment in Parkinson's disease. *Neurology* 38: 540-545
- Wester RC, Maibach HI (1983) Cutaneous pharmacokinetics: 10 steps to percutaneous absorption. *Drug metabolism reviews* 14: 169-205
- Westerink BHC, van Es TP, Spaan SJ (1982) Effects of drugs interfering with dopamine and noradrenaline biosynthesis on the endogenous 3,4-hydroxyphenylalanine levels in rat brain. *J Neurochem* 39: 44-51
- Westerink BHC, Damsma G, Rollema H, de Vries JB, Horn AS (1987) Scope and limitations of in vivo brain dialysis: A comparison of its application to various neurotransmitter systems. *Life Sci* 41: 1763-1776
- Westerink BHC, Tuntler J, Damsma G, Rollema H, de Vries JB (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. *Naunyn-Schmiedeberg's Arch Pharmacol* 336: 502-507
- Westerink BHC, de Vries JB, Duran R (1990) Use of microdialysis for monitoring tyrosine hydroxylase activity in the brain of conscious rats. *J Neurochem* 54: 381-387
- Widner H, Brundin P, Rehnroos S, Gustavii B, Leenders KL, Sawle G, Rothwell JC, Marsden CD, Björklund A, Lindvall O (1991) Transplanted allogeneic fetal dopamine neurons survive and improve motor function in idiopathic Parkinson's disease. *Transplant Proc* 23: 793-795
- Wiechers JW, Drenth BFH, Jonkman JHG, De Zeeuw RA (1990) Percutaneous absorption, metabolic profiling, and excretion of the penetration enhancer Azone after multiple

- dosing of an Azone-containing triamcinolone acetonide cream in humans. *J Pharm Sci* 79: 111-115
- Wilbur R, Kulik FA, Kulik AV (1988) Noradrenergic effects in tardive dyskinesia, akathisia and pseudoparkinsonism via the limbic system and basal ganglia. *Prog Neuro-Psychopharmacol & Biol Psychiat* 12: 849-864
- Wolfson LI, Escriva A (1976) Clearance of 3-methoxy-4-hydroxyphenylglycol from the cerebral fluid. *Neurology* 26: 781-784
- Wolthers BG, Verhagen-Kamerbeek WDJ, van Beusekom CM, Eishof F, De Ruyter-Buithuis AW, Brunt ERP, Lakke JPF (1993) Quantitative determination of the dopamine agonist lisuride in plasma using high-performance liquid chromatography with fluorescence detection. *J Chromat* 622: 33-38
- Wolthers ECH, Kuiper MA, Horstink MWIM (1992) Selegiline bij de ziekte van Parkinson; symptomatisch of causaal effect? *Ned Tijdschr Geneesk* 136: 1544-1547
- Yamamoto M, Ogawa N, Ujike H (1986) Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxyphenylglycol. Concentration in patients with Parkinson's disease. *J Neurol Sci* 73: 39-44
- Yergey JA, Heyes MP (1990) Brain eicosanoid formation following acute penetration injury as studied by in vivo microdialysis. *J Cereb Blood Flow Metab* 10: 143-146
- Yntema OP, Korf J (1987) Transient suppression by stress of haloperidol-induced catalepsy by the activation of the adrenal medulla. *Psychopharmacology* 91: 131-134
- Yokochi M, Narabayashi H, Iizuka R, Nagatsu T (1984) Juvenile parkinsonism - some clinical pharmacological and neuropathological aspects. *Adv Neurol* 40: 407-413
- Yokoo H, Tanaka M, Yoshida M, Tsuda A, Tanaka T, Mizoguchi K (1990) Direct evidence of conditioned fear-elicited enhancement of noradrenaline release in the rat hypothalamus assessed by intracranial microdialysis. *Brain Res* 536: 305-308
- Yoshida M, Noguchi S, Kuramoto S (1989) L-threo-3,4-dihydroxyphenylserine treatment for gait apraxia in parkinsonian patients. *Kurume Med J* 36: 67-74
- Zetterström T, Ungerstedt U (1984) Effects of apomorphine on the in vivo release of dopamine and its metabolites, studied by brain dialysis. *Eur J Pharmacol* 97: 29-36
- Zetterström T, Sharp T, Ungerstedt U (1984) Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis. *Eur J Pharmacol* 106: 27-37
- Zetterström T, Sharp T, Ungerstedt U (1986) Effect of dopamine D-1 and D-2 receptor selective drugs on dopamine release and metabolism in rat striatum in vivo. *Naunyn-Schmiedeberg's Arch Pharmacol* 334: 117-124
- Zhang F, Dryhurst G (1993) Oxidation chemistry of dopamine: Possible insights into age-dependent loss of dopaminergic nigrostriatal neurons. *Bioorganic Chem* 21 (4): 392-410
- Zieher LM, Jaim-Écheverry G (1980) Neurotoxicity of N-(2-chloroethyl)-N-ethyl-2-bromo-benzylamine hydrochloride (DSP₄) on noradrenergic neurons is mimicked by its cyclic aziridinium derivative. *Eur J Pharmacol* 65: 249-256
- Zürcher G, Dingemans J, Da Prada M (1991) Ro 40-7592, a potent inhibitor of extracerebral and brain catechol-O-methyltransferase: Preclinical and clinical findings. In: Agnoli A, Campanella G (eds) *New Developments in Therapy of Parkinson's Disease*. John Libbey CIC, Rome, 37-43
- Zürcher G, Dingemans J, Da Prada M (1993) Potent COMT inhibition by Ro 40-7592 in the periphery and the brain. *Adv Neurol* 60: 641-647
- Zweifler AJ, Julius S (1982) Increased platelet catecholamine content in pheochromocytoma. *New Engl J Med* 306: 890-894
- Zweig RM, Cardillo E, Cohen M, Giere S, Hedreen JC (1993) The locus coeruleus and dementia in Parkinson's disease. *Neurology* 43: 986-991